AU6060899A - Human complement c3-degrading polypeptide from (streptococcus pneumoniae) - Google Patents
Human complement c3-degrading polypeptide from (streptococcus pneumoniae) Download PDFInfo
- Publication number
- AU6060899A AU6060899A AU60608/99A AU6060899A AU6060899A AU 6060899 A AU6060899 A AU 6060899A AU 60608/99 A AU60608/99 A AU 60608/99A AU 6060899 A AU6060899 A AU 6060899A AU 6060899 A AU6060899 A AU 6060899A
- Authority
- AU
- Australia
- Prior art keywords
- polypeptide
- seq
- kda
- pneumoniae
- nucleic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims description 254
- 102000004196 processed proteins & peptides Human genes 0.000 title claims description 247
- 229920001184 polypeptide Polymers 0.000 title claims description 236
- 230000000295 complement effect Effects 0.000 title claims description 21
- 241000193998 Streptococcus pneumoniae Species 0.000 title description 9
- 229940031000 streptococcus pneumoniae Drugs 0.000 title description 7
- 150000007523 nucleic acids Chemical group 0.000 claims description 68
- 210000004027 cell Anatomy 0.000 claims description 47
- 150000001413 amino acids Chemical class 0.000 claims description 46
- 108020004707 nucleic acids Proteins 0.000 claims description 45
- 102000039446 nucleic acids Human genes 0.000 claims description 45
- 238000000034 method Methods 0.000 claims description 34
- 239000000203 mixture Substances 0.000 claims description 31
- 108020004414 DNA Proteins 0.000 claims description 30
- 230000004936 stimulating effect Effects 0.000 claims description 27
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 24
- 210000000987 immune system Anatomy 0.000 claims description 18
- 101000901154 Homo sapiens Complement C3 Proteins 0.000 claims description 16
- 239000013598 vector Substances 0.000 claims description 16
- 208000015181 infectious disease Diseases 0.000 claims description 15
- 239000002773 nucleotide Substances 0.000 claims description 15
- 125000003729 nucleotide group Chemical group 0.000 claims description 15
- 241000894006 Bacteria Species 0.000 claims description 13
- 238000009396 hybridization Methods 0.000 claims description 13
- 102000000989 Complement System Proteins Human genes 0.000 claims description 12
- 108010069112 Complement System Proteins Proteins 0.000 claims description 12
- 230000015556 catabolic process Effects 0.000 claims description 12
- 238000006731 degradation reaction Methods 0.000 claims description 12
- 241000124008 Mammalia Species 0.000 claims description 9
- 241001465754 Metazoa Species 0.000 claims description 8
- 230000028993 immune response Effects 0.000 claims description 8
- 230000001404 mediated effect Effects 0.000 claims description 8
- 241000283707 Capra Species 0.000 claims description 6
- 230000002401 inhibitory effect Effects 0.000 claims description 6
- 238000002689 xenotransplantation Methods 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 241000287828 Gallus gallus Species 0.000 claims description 4
- 206010061218 Inflammation Diseases 0.000 claims description 4
- 241000283973 Oryctolagus cuniculus Species 0.000 claims description 4
- 230000036755 cellular response Effects 0.000 claims description 4
- 210000002919 epithelial cell Anatomy 0.000 claims description 4
- 230000004054 inflammatory process Effects 0.000 claims description 4
- 230000001225 therapeutic effect Effects 0.000 claims description 4
- 102000053602 DNA Human genes 0.000 claims description 3
- 210000003719 b-lymphocyte Anatomy 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- 210000003527 eukaryotic cell Anatomy 0.000 claims description 3
- 230000005867 T cell response Effects 0.000 claims description 2
- 210000002889 endothelial cell Anatomy 0.000 claims description 2
- 210000000056 organ Anatomy 0.000 claims description 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 description 66
- 102000004169 proteins and genes Human genes 0.000 description 45
- 235000018102 proteins Nutrition 0.000 description 44
- 239000012634 fragment Substances 0.000 description 43
- 230000000593 degrading effect Effects 0.000 description 33
- 239000000499 gel Substances 0.000 description 28
- 235000001014 amino acid Nutrition 0.000 description 27
- 229940024606 amino acid Drugs 0.000 description 26
- 229960005486 vaccine Drugs 0.000 description 26
- 230000000694 effects Effects 0.000 description 22
- 239000013612 plasmid Substances 0.000 description 22
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 21
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 18
- 108700026244 Open Reading Frames Proteins 0.000 description 15
- 239000013615 primer Substances 0.000 description 14
- 241000699670 Mus sp. Species 0.000 description 12
- 238000011534 incubation Methods 0.000 description 12
- 239000000872 buffer Substances 0.000 description 11
- 230000000692 anti-sense effect Effects 0.000 description 10
- 230000001580 bacterial effect Effects 0.000 description 10
- 108010040473 pneumococcal surface protein A Proteins 0.000 description 10
- 239000000523 sample Substances 0.000 description 10
- 241000588724 Escherichia coli Species 0.000 description 9
- 239000006166 lysate Substances 0.000 description 9
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 8
- 229940035032 monophosphoryl lipid a Drugs 0.000 description 8
- 238000001262 western blot Methods 0.000 description 8
- 239000012130 whole-cell lysate Substances 0.000 description 8
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 7
- 108020004705 Codon Proteins 0.000 description 7
- 238000003556 assay Methods 0.000 description 7
- 229940098773 bovine serum albumin Drugs 0.000 description 7
- 239000013604 expression vector Substances 0.000 description 7
- 230000014509 gene expression Effects 0.000 description 7
- 229930027917 kanamycin Natural products 0.000 description 7
- 229960000318 kanamycin Drugs 0.000 description 7
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 7
- 229930182823 kanamycin A Natural products 0.000 description 7
- 230000002829 reductive effect Effects 0.000 description 7
- 238000003776 cleavage reaction Methods 0.000 description 6
- 102000057770 human C3 Human genes 0.000 description 6
- 230000007017 scission Effects 0.000 description 6
- 239000006228 supernatant Substances 0.000 description 6
- 241000972773 Aulopiformes Species 0.000 description 5
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 5
- 241001460678 Napo <wasp> Species 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 238000001962 electrophoresis Methods 0.000 description 5
- 150000004676 glycans Chemical class 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 229920001282 polysaccharide Polymers 0.000 description 5
- 239000005017 polysaccharide Substances 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 235000019515 salmon Nutrition 0.000 description 5
- 238000006467 substitution reaction Methods 0.000 description 5
- 238000002560 therapeutic procedure Methods 0.000 description 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
- 108010071134 CRM197 (non-toxic variant of diphtheria toxin) Proteins 0.000 description 4
- 102100022133 Complement C3 Human genes 0.000 description 4
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 4
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 4
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 4
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 4
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 4
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 4
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 4
- 239000002671 adjuvant Substances 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 239000013256 coordination polymer Substances 0.000 description 4
- 230000034994 death Effects 0.000 description 4
- 231100000517 death Toxicity 0.000 description 4
- 230000002163 immunogen Effects 0.000 description 4
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 4
- 230000001717 pathogenic effect Effects 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 108091008146 restriction endonucleases Proteins 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 3
- 108010060123 Conjugate Vaccines Proteins 0.000 description 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 3
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 3
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 3
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 3
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 3
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 3
- 208000035109 Pneumococcal Infections Diseases 0.000 description 3
- 108091081024 Start codon Proteins 0.000 description 3
- 239000007983 Tris buffer Substances 0.000 description 3
- NWMHDZMRVUOQGL-CZEIJOLGSA-N almurtide Chemical compound OC(=O)CC[C@H](C(N)=O)NC(=O)[C@H](C)NC(=O)CO[C@@H]([C@H](O)[C@H](O)CO)[C@@H](NC(C)=O)C=O NWMHDZMRVUOQGL-CZEIJOLGSA-N 0.000 description 3
- 239000000427 antigen Substances 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 238000009835 boiling Methods 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 229940031670 conjugate vaccine Drugs 0.000 description 3
- 230000009089 cytolysis Effects 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 230000008021 deposition Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 108020001507 fusion proteins Proteins 0.000 description 3
- 102000037865 fusion proteins Human genes 0.000 description 3
- 230000005847 immunogenicity Effects 0.000 description 3
- 210000003000 inclusion body Anatomy 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 239000002198 insoluble material Substances 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 3
- 244000052769 pathogen Species 0.000 description 3
- 108091033319 polynucleotide Proteins 0.000 description 3
- 102000040430 polynucleotide Human genes 0.000 description 3
- 239000002157 polynucleotide Substances 0.000 description 3
- 230000001681 protective effect Effects 0.000 description 3
- 238000011282 treatment Methods 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- QFVHZQCOUORWEI-UHFFFAOYSA-N 4-[(4-anilino-5-sulfonaphthalen-1-yl)diazenyl]-5-hydroxynaphthalene-2,7-disulfonic acid Chemical compound C=12C(O)=CC(S(O)(=O)=O)=CC2=CC(S(O)(=O)=O)=CC=1N=NC(C1=CC=CC(=C11)S(O)(=O)=O)=CC=C1NC1=CC=CC=C1 QFVHZQCOUORWEI-UHFFFAOYSA-N 0.000 description 2
- 101710117373 92 kDa protein Proteins 0.000 description 2
- 108010088751 Albumins Proteins 0.000 description 2
- 102000009027 Albumins Human genes 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 2
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 2
- 241000283715 Damaliscus lunatus Species 0.000 description 2
- 241000672609 Escherichia coli BL21 Species 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 2
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 2
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- 108010052285 Membrane Proteins Proteins 0.000 description 2
- 108700015872 N-acetyl-nor-muramyl-L-alanyl-D-isoglutamine Proteins 0.000 description 2
- 239000000020 Nitrocellulose Substances 0.000 description 2
- 206010035664 Pneumonia Diseases 0.000 description 2
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 2
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 2
- 238000002105 Southern blotting Methods 0.000 description 2
- 241000194017 Streptococcus Species 0.000 description 2
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 2
- 239000004473 Threonine Substances 0.000 description 2
- 229920004890 Triton X-100 Polymers 0.000 description 2
- 239000013504 Triton X-100 Substances 0.000 description 2
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 2
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 2
- 239000011543 agarose gel Substances 0.000 description 2
- 235000004279 alanine Nutrition 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- ILRRQNADMUWWFW-UHFFFAOYSA-K aluminium phosphate Chemical compound O1[Al]2OP1(=O)O2 ILRRQNADMUWWFW-UHFFFAOYSA-K 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000005875 antibody response Effects 0.000 description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
- 235000009582 asparagine Nutrition 0.000 description 2
- 229960001230 asparagine Drugs 0.000 description 2
- 235000003704 aspartic acid Nutrition 0.000 description 2
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 235000020958 biotin Nutrition 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- 229940041514 candida albicans extract Drugs 0.000 description 2
- 239000004202 carbamide Substances 0.000 description 2
- 210000002421 cell wall Anatomy 0.000 description 2
- 229960001231 choline Drugs 0.000 description 2
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 2
- 239000013599 cloning vector Substances 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- 239000012228 culture supernatant Substances 0.000 description 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 2
- 235000018417 cysteine Nutrition 0.000 description 2
- 230000001086 cytosolic effect Effects 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- 238000009585 enzyme analysis Methods 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 235000013922 glutamic acid Nutrition 0.000 description 2
- 239000004220 glutamic acid Substances 0.000 description 2
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 2
- 229960000310 isoleucine Drugs 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 238000011068 loading method Methods 0.000 description 2
- 230000002101 lytic effect Effects 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 210000003739 neck Anatomy 0.000 description 2
- 229920001220 nitrocellulos Polymers 0.000 description 2
- 230000001662 opsonic effect Effects 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 229920002401 polyacrylamide Polymers 0.000 description 2
- 229940031937 polysaccharide vaccine Drugs 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000002864 sequence alignment Methods 0.000 description 2
- 235000004400 serine Nutrition 0.000 description 2
- 239000001509 sodium citrate Substances 0.000 description 2
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 235000008521 threonine Nutrition 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 238000013519 translation Methods 0.000 description 2
- 239000003656 tris buffered saline Substances 0.000 description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
- 235000002374 tyrosine Nutrition 0.000 description 2
- 239000011534 wash buffer Substances 0.000 description 2
- 239000012138 yeast extract Substances 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- YHQZWWDVLJPRIF-JLHRHDQISA-N (4R)-4-[[(2S,3R)-2-[acetyl-[(3R,4R,5S,6R)-3-amino-4-[(1R)-1-carboxyethoxy]-5-hydroxy-6-(hydroxymethyl)oxan-2-yl]amino]-3-hydroxybutanoyl]amino]-5-amino-5-oxopentanoic acid Chemical compound C(C)(=O)N([C@@H]([C@H](O)C)C(=O)N[C@H](CCC(=O)O)C(N)=O)C1[C@H](N)[C@@H](O[C@@H](C(=O)O)C)[C@H](O)[C@H](O1)CO YHQZWWDVLJPRIF-JLHRHDQISA-N 0.000 description 1
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- XOGPDSATLSAZEK-UHFFFAOYSA-N 2-Aminoanthraquinone Chemical compound C1=CC=C2C(=O)C3=CC(N)=CC=C3C(=O)C2=C1 XOGPDSATLSAZEK-UHFFFAOYSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 108020004491 Antisense DNA Proteins 0.000 description 1
- 101100519158 Arabidopsis thaliana PCR2 gene Proteins 0.000 description 1
- 201000001178 Bacterial Pneumonia Diseases 0.000 description 1
- 208000034309 Bacterial disease carrier Diseases 0.000 description 1
- 108010039939 Cell Wall Skeleton Proteins 0.000 description 1
- 229930186147 Cephalosporin Natural products 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 108700010070 Codon Usage Proteins 0.000 description 1
- 108010028780 Complement C3 Proteins 0.000 description 1
- 102000016918 Complement C3 Human genes 0.000 description 1
- 108010078015 Complement C3b Proteins 0.000 description 1
- 102000005927 Cysteine Proteases Human genes 0.000 description 1
- 108010005843 Cysteine Proteases Proteins 0.000 description 1
- 108020001019 DNA Primers Proteins 0.000 description 1
- 108020003215 DNA Probes Proteins 0.000 description 1
- 239000003155 DNA primer Substances 0.000 description 1
- 239000003298 DNA probe Substances 0.000 description 1
- 241000224432 Entamoeba histolytica Species 0.000 description 1
- 241000588722 Escherichia Species 0.000 description 1
- 206010018364 Glomerulonephritis Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 208000031886 HIV Infections Diseases 0.000 description 1
- 208000037357 HIV infectious disease Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 108010003272 Hyaluronate lyase Proteins 0.000 description 1
- 102000001974 Hyaluronidases Human genes 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- 108010054278 Lac Repressors Proteins 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 206010027202 Meningitis bacterial Diseases 0.000 description 1
- HRNLUBSXIHFDHP-UHFFFAOYSA-N N-(2-aminophenyl)-4-[[[4-(3-pyridinyl)-2-pyrimidinyl]amino]methyl]benzamide Chemical compound NC1=CC=CC=C1NC(=O)C(C=C1)=CC=C1CNC1=NC=CC(C=2C=NC=CC=2)=N1 HRNLUBSXIHFDHP-UHFFFAOYSA-N 0.000 description 1
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
- 108700020354 N-acetylmuramyl-threonyl-isoglutamine Proteins 0.000 description 1
- 102000005348 Neuraminidase Human genes 0.000 description 1
- 108010006232 Neuraminidase Proteins 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 208000005141 Otitis Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 102000016387 Pancreatic elastase Human genes 0.000 description 1
- 108010067372 Pancreatic elastase Proteins 0.000 description 1
- 241000282320 Panthera leo Species 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 101710099976 Photosystem I P700 chlorophyll a apoprotein A1 Proteins 0.000 description 1
- 206010058859 Pneumococcal bacteraemia Diseases 0.000 description 1
- 101710183389 Pneumolysin Proteins 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 241000607768 Shigella Species 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 102400000368 Surface protein Human genes 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 108020005038 Terminator Codon Proteins 0.000 description 1
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 241000607598 Vibrio Species 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 241000607734 Yersinia <bacteria> Species 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 239000003816 antisense DNA Substances 0.000 description 1
- 230000003190 augmentative effect Effects 0.000 description 1
- 238000000211 autoradiogram Methods 0.000 description 1
- 201000009904 bacterial meningitis Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000006287 biotinylation Effects 0.000 description 1
- 238000007413 biotinylation Methods 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 210000004520 cell wall skeleton Anatomy 0.000 description 1
- 229940124587 cephalosporin Drugs 0.000 description 1
- 150000001780 cephalosporins Chemical class 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000013611 chromosomal DNA Substances 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 230000001332 colony forming effect Effects 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000024203 complement activation Effects 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 238000005336 cracking Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 1
- 208000019258 ear infection Diseases 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 229940007078 entamoeba histolytica Drugs 0.000 description 1
- DNJIEGIFACGWOD-UHFFFAOYSA-N ethyl mercaptane Natural products CCS DNJIEGIFACGWOD-UHFFFAOYSA-N 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000013613 expression plasmid Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000013210 hematogenous Diseases 0.000 description 1
- 238000002744 homologous recombination Methods 0.000 description 1
- 230000006801 homologous recombination Effects 0.000 description 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 1
- 229960002773 hyaluronidase Drugs 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000000984 immunochemical effect Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 238000002743 insertional mutagenesis Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- IZWSFJTYBVKZNK-UHFFFAOYSA-N lauryl sulfobetaine Chemical compound CCCCCCCCCCCC[N+](C)(C)CCCS([O-])(=O)=O IZWSFJTYBVKZNK-UHFFFAOYSA-N 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 239000013586 microbial product Substances 0.000 description 1
- JMUHBNWAORSSBD-WKYWBUFDSA-N mifamurtide Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCCCCCCCCCC)COP(O)(=O)OCCNC(=O)[C@H](C)NC(=O)CC[C@H](C(N)=O)NC(=O)[C@H](C)NC(=O)[C@@H](C)O[C@H]1[C@H](O)[C@@H](CO)OC(O)[C@@H]1NC(C)=O JMUHBNWAORSSBD-WKYWBUFDSA-N 0.000 description 1
- 229960005225 mifamurtide Drugs 0.000 description 1
- 108700007621 mifamurtide Proteins 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- SLCVBVWXLSEKPL-UHFFFAOYSA-N neopentyl glycol Chemical compound OCC(C)(C)CO SLCVBVWXLSEKPL-UHFFFAOYSA-N 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 229920002113 octoxynol Polymers 0.000 description 1
- 230000014207 opsonization Effects 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000006179 pH buffering agent Substances 0.000 description 1
- 230000000242 pagocytic effect Effects 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 210000001539 phagocyte Anatomy 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 238000007747 plating Methods 0.000 description 1
- 229960001973 pneumococcal vaccines Drugs 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000000135 prohibitive effect Effects 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 235000019833 protease Nutrition 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 239000006152 selective media Substances 0.000 description 1
- 239000013605 shuttle vector Substances 0.000 description 1
- 229940031439 squalene Drugs 0.000 description 1
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- XETCRXVKJHBPMK-MJSODCSWSA-N trehalose 6,6'-dimycolate Chemical compound C([C@@H]1[C@H]([C@H](O)[C@@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](COC(=O)C(CCCCCCCCCCC3C(C3)CCCCCCCCCCCCCCCCCC)C(O)CCCCCCCCCCCCCCCCCCCCCCCCC)O2)O)O1)O)OC(=O)C(C(O)CCCCCCCCCCCCCCCCCCCCCCCCC)CCCCCCCCCCC1CC1CCCCCCCCCCCCCCCCCC XETCRXVKJHBPMK-MJSODCSWSA-N 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Wood Science & Technology (AREA)
- Rheumatology (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Enzymes And Modification Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Description
WO 00/17370 PCT/US99/22362 HUMAN COMPLEMENT C3-DEGRADING POLYPEPTIDE FROM STREPTOCOCCUS PNEUMONIAE 5 Field of the Invention This invention relates to Streptococcus pneumoniae and in particular this invention relates to the identification of an S. pneumoniae polypeptide that is capable of degrading human complement protein C3. 10 Background of the Invention Respiratory infection with the bacterium Streptococcus pneumoniae (S. pneumoniae) leads to an estimated 500,000 cases of pneumonia and 47,000 deaths annually. Those persons at highest risk of bacteremic pneumococcal 15 infection are infants under two years of age, individuals with a compromised immune system and the elderly. In these populations, S. pneumoniae is the leading cause of bacterial pneumonia and meningitis. Moreover, S. pneumoniae is the major bacterial cause of ear infections in children of all ages. Both children and the elderly share defects in the synthesis of protective antibodies to 20 pneumococcal capsular polysaccharide after either bacterial colonization, local or systemic infection, or vaccination with purified polysaccharides. S. pneumoniae is the leading cause of invasive bacterial respiratory disease in both adults and children with HIV infection and produces hematogenous infection in these patients (Connor et al. Current Topics in AIDS 1987; 1:185-209 and Janoff 25 et al. Ann. Intern. Med. 1992; 117(4):314-324). Individuals who demonstrate the greatest risk for severe infection are not able to make antibodies to the current capsular polysaccharide vaccines. As a result, there are now four conjugate vaccines in clinical trial. Conjugate vaccines consist of pneumococcal capsular polysaccharides coupled to protein 30 carriers or adjuvants in an attempt to boost the antibody response. However, there are other potential problems with conjugate vaccines currently in clinical trials. For example, pneumococcal serotypes that are most prevalent ir the United States are differe- . from the serotypes tb-' _,e most co- _aon in places WO 00/17370 PCT/US99/22362 2 such as Israel, Western Europe, South Africa, or Scandinavia. Therefore, vaccines that may be useful in one geographic locale may not be useful in another. The potential need to modify currently available capsular polysaccharide vaccines or to develop protein conjugates for capsular vaccines 5 to suit geographic serotype variability entails prohibitive financial and technical complications. Thus, the search for immunogenic, surface-exposed proteins that are conserved worldwide among a variety of virulent serotypes is of prime importance to the prevention of pneumococcal infection and to the formulation of broadly protective pneumococcal vaccines. Moreover, the emergence of 10 penicillin and cephalosporin-resistant pneumococci on a worldwide basis makes the need for effective vaccines even more exigent (Baquero et al. J Antimicrob. Chemother. 1991;28S;31-8). Several pneumococcal proteins have been proposed for conjugation to pneumococcal capsular polysaccharide or as single immunogens to stimulate 15 immunity against S. pneumoniae. Surface proteins that are reported to be involved in adhesion of S. pneumoniae to epithelial cells of the respiratory tract include PsaA, PspC/CBP112, and IgAl proteinase (Sampson et al. Infect. Immun. 1994;62:319-324, Sheffield et al. Microb. Pathogen. 1992; 13: 261-9, and Wani, et al. Infect. Immun. 1996; 64:3967-3974). Antibodies to these 20 adhesins could inhibit binding of pneumococci to respiratory epithelial cells and thereby reduce colonization. Other cytosolic pneumococcal proteins such as pneumolysin, autolysin, neuraminidase, or hyaluronidase are proposed as vaccine antigens because antibodies could potentially block the toxic effects of these proteins in patients infected with S. pneumoniae. However, these proteins 25 are typically not located on the surface of S. pneumoniae, rather they are secreted or released from the bacterium as the cells lyse and die (Lee et al. Vaccine 1994; 12:875-8 and Berry et al. Infect. Immun. 1994; 62:1101-1108). While use of these cytosolic proteins as immunogens might ameliorate late consequences of S. pneumoniae infection, antibodies to these proteins would neither promote 30 pneumococcal death nor prevent initial or subsequent pneumococcal colonization. A prototypic surface protein that is being te-d as a pnevraiococcal WO 00/17370 PCT/US99/22362 3 vaccine is the pneumococcal surface protein A (PspA). PspA is a heterogeneous protein of about 70-140 kDa. The PspA structure includes an alpha helix at the amino terminus, followed by a proline-rich sequence, and terminates in a series of 11 choline-binding repeats at the carboxy-terminus. Although much 5 information regarding its structure is available, PspA is not structurally conserved among a variety of pneumococcal serotypes, and its function is entirely unknown (Yother et al. J. Bacteriol. 1992;174:601-9 and Yother J. Bacteriol. 1994;176:2976-2985). Studies have confirmed the immunogenicity of PspA in animals (McDaniel et al. Microb. Pathogen. 1994; 17;323-337). 10 Despite the immunogenicity of PspA, the heterogeneity of PspA, its existence in four structural groups (or clades), and its uncharacterized function complicate its ability to be used as a vaccine antigen. In patients who cannot make protective antibodies to the type-specific polysaccharide capsule, the third component of complement, C3, and the 15 associated proteins of the alternative complement pathway constitute the first line of host defense against S. pneumoniae infection. Because complement proteins cannot penetrate the rigid cell wall of S. pneumoniae, deposition of opsonic C3b on the pneumococcal surface is the principal mediator of pneumococcal clearance. Interactions of pneumococci with plasma C3 are 20 known to occur during pneumococcal bacteremia, when the covalent binding of C3b, the opsonically active fragment of C3, initiates phagocytic recognition and ingestion (Johnston et al. J. Exp. Med 1969;129:1275-1290, Hasin HE, J. Immunol. 1972; 109:26-31 and Hostetter et al. J. Infect. Dis. 1984; 150:653-61). C3b deposits on the pneumococcal capsule, as well as on the cell wall. This 25 method for controlling S. pneumoniae infection is fairly inefficient. Methods for augmenting S. pneumoniae opsonization could improve the disease course induced by this organism. There currently exists a strong need for methods and therapies to limit S. pneumoniae infection. 30 Summary of the Invention This invention relates to the identification u ;d use ofe f nily of human WO 00/17370 PCT/US99/223 6 2 4 complement C3-degrading polypeptides (e.g., proteins) expressed by S. pneumoniae. The polypeptides preferably have a molecular weight of about 15 kDa to about 25 kDa, or about 75 kDa to about 95 kDa, as determined, for example, on a 10% SDS polyacrylamide gel. The invention includes a number 5 of polypeptides isolatable from different C3-degrading strains of S. pneumoniae. In one aspect, the invention relates to an isolated polypeptide having at least 80% sequence identity with SEQ ID NO:2 or SEQ ID NO:5. In a preferred embodiment, the polypeptide is isolated from S. pneumoniae or alternatively the polypeptide is a recombinant polypeptide. Preferably, the isolated polypeptide 10 degrades human complement protein C3. A preferred polypeptide of this invention is an isolated polypeptide having an amino acid sequence that includes SEQ ID NO:2 or SEQ ID NO:5, and more preferably, is SEQ ID NO:2 or SEQ ID NO: 5. The term "isolated" as used herein refers to a naturally occurring species that has been removed from its natural environment, as well as to 15 synthetic species. The term "polypeptide" as used herein includes peptides, polypeptides, and proteins, regardless of length. Preferably, the polypeptides of the invention include one or more functional units, which encompasses polypeptides that degrade human complement protein C3. Thus, the invention also relates to polypeptide fragments isolated from a 20 C3-degrading protein of this invention. Such fragments are encompassed by the term "polypeptide" as used herein. Preferably, the invention provides polypeptides of at least 15 sequential amino acids derived from a protein that has at least 80% sequence identity with SEQ ID NO:2 or SEQ ID NO:5, and more preferably, polypeptides of at least 15 sequential amino acids of SEQ ID NO:2 25 or SEQ ID NO:5. In another aspect of this invention, preferred polypeptides are capable of degrading human complement protein C3. In another aspect, the invention relates to an isolated polypeptide that preferably degrades human complement protein C3, wherein nucleic acid encoding the isolated polypeptide hybridizes to at least a portion of SEQ ID 30 NO:1 or SEQ ID NO:4 or their complementary strands under highly stringent hybridization conditions. Preferably, the polypeptide includes at least 15 WO 00/17370 PCT/US99/2236 2 5 sequential amino acids, which are, more preferably, of SEQ ID NO:2 or SEQ ID NO:5. In an additional aspect, this invention relates to polypeptides that have reduced human C3 degradation activity or which do not degrade human C3; 5 however, the nucleic acids encoding this group of polypeptides each include a nucleotide sequence that hybridizes to either the nucleic acids that encode human C3 degrading polypeptides, or the complementary strands for each nucleic acid. This latter group of polypeptides having reduced or no human C3 degrading activity are referred to herein as "non-degrading" polypeptides. The non 10 degrading polypeptides may differ from C3 degrading polypeptides by one or more amino acids. This amino acid change may be a substitution, alteration, or deletion of one or more amino acids. Various types of amino acid changes are discussed herein. Nucleic acids encoding the non-degrading polypeptides are alternatively preferred embodiments of this invention. 15 The invention also relates to an immune system stimulating composition (preferably, a vaccine) comprising an effective amount of an immune system stimulating polypeptide of the present invention, which is preferably isolated from S. pneumoniae, and a therapeutically acceptable carrier. In one embodiment, the immune system stimulating composition or vaccine further 20 comprises at least one other immune system stimulating polypeptide isolated from S. pneumoniae. The invention further relates to an antibody capable of binding (typically, specifically binding) to a polypeptide (at least a portion thereof) of the present invention. In one embodiment, the antibody is a monoclonal antibody and in 25 another embodiment, the antibody is a polyclonal antibody. In another embodiment the antibody is an antibody fragment. The antibody or antibody fragments can be obtained from a mouse, a rat, a goat, a chicken, a human, or a rabbit. The invention also relates to an isolated nucleic acid molecule (i.e., a 30 polynucleotide, which can be single stranded or double stranded, and which can be a part, or fragment, of a larger molecule such as a vector) capable of hybridizing to at least a portion of SEQ ID ;: or SEO) D NO:4 or their WO 00/17370 PCTIUS99/2236 2 6 complimentary strands under highly stringent hybridization conditions. As used herein, highly stringent hybridization conditions include, for example, 6XSSC, 5X Denhardt, 0.5% SDS, and 100 pg/ml fragmented and denatured salmon sperm DNA hybridized overnight at 65*C and washed in 2X SSC, 0.1% SDS 5 one time at room temperature for about 10 minutes followed by one time at 65*C for about 15 minutes followed by at least one wash in 0.2XSSC, 0.1% SDS at room temperature for at least 3-5 minutes. In one embodiment, the nucleic acid molecule is isolated from S. pneumoniae and in another embodiment, the nucleic acid molecule encodes a polypeptide. In one embodiment, the polypeptide 10 degrades human complement protein C3. In another embodiment, the nucleic acid molecule encodes a polypeptide that does not degrade human complement C3. In another embodiment, the nucleic acid molecule is in a vector (i.e., it is a fragment of a nucleic acid vector). The vector can be an expression vector 15 capable of producing a polypeptide. Cells containing the nucleic acid molecule are also contemplated in this invention. In one embodiment, the cell is a bacterium or a eukaryotic cell. The invention further relates to an isolated nucleic acid molecule comprising the nucleic acid sequence of SEQ ID NO: 1 or SEQ ID NO:4, or their 20 complementary strands. The invention further relates to an RNA molecule transcribed by a double-stranded DNA sequence comprising SEQ ID NO:1 or SEQ ID NO:4. In another aspect of this invention, the invention relates to a method for producing an immune response to S. pneumoniae in a mammal (particularly a 25 human). The method includes: administering to a mammal a composition comprising a therapeutically effective amount of a polypeptide of the present invention, and a pharmaceutically acceptable carrier, to produce an immune response to the polypeptide. The immune response can be a B cell response, a T cell response, an epithelial response, or an endothelial response. In a preferred 30 embodiment, the composition is a vaccine composition. Preferably the polypeptide is at least 15 amino acids in length and also preferably the composition further comprises at least r other imr' .ie system stimulating WO 00/17370 PCTIUS99/223 6 2 7 polypeptide from S. pneumoniae. In one embodiment, the polypeptide comprises at least 15 amino acids of SEQ ID NO:2 or SEQ ID NO: 5. The invention further relates to an isolated polypeptide of about 15 kDa to about 25 kDa, or about 75 kDa to about 95 kDa, from Streptococcus 5 pneumoniae that is capable of degrading human complement C3 and to a method for inhibiting Streptococcus pneumoniae-mediated C3 degradation. The method includes contacting a Streptococcus pneumoniae bacterium with antibody capable of binding to a polypeptide (at least a portion thereof) of the present invention. 10 The invention also relates to a method for inhibiting C3-mediated inflammation and rejection in xenotransplantation. The method includes expressing on the surface of an organ of an animal used in xenotransplantation a polypeptide of the present invention. This method is particularly advantageous for causing, for example, the kidneys of pigs to express the polypeptide 15 described herein and thereby to inhibit C3 mediated inflammation after xenotransplantation. The invention also relates to an isolated nucleic acid molecule that contains a region of at least 15 nucleotides which hybridize under highly stringent hybridization conditions to at least a portion of a nucleic acid sequence 20 of SEQ ID NO: 1 or SEQ ID NO:4 or their complementary strands. The invention also relates to isolated DNA molecules or primers having the nucleic acid sequences as shown in SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8 AND SEQ ID NO:9. 25 Brief Description of the Figures Figure 1 provides the nucleic acid sequence of the translated portion of a C3-degrading polypeptide (approximately 20 kDa) gene of this invention (SEQ ID NO:1). Figure 2 provides the amino acid sequence of a C3-degrading 30 polypeptide (approximately 20 kDa) of this invention (SEQ ID NO:2). Figure 3 diagrams the amino acid sequence of a C3-degrading polypeptide (approximately 20 kDa- st' ioned withl the nucleic acid sequence WO 00/17370 PCTIUS99/223 6 2 8 (double stranded) encoding a C3-degrading polypeptide according to this invention (SEQ ID NOS:1-3 wherein SEQ ID NO:3 is the complement of SEQ ID NO:1). Figure 4 provides the nucleic acid sequence for a predicted 92 kDa amino 5 acid sequence (SEQ ID NO:4). Figure 5 provides the predicted 92 kDa amino acid sequence (SEQ ID NO:5). Figure 6 shows sequence alignments of SEQ ID NO:1 and a portion of SEQ ID NO:4. 10 Figure 7 shows sequence alignment of SEQ ID NO:2 with a portion of SEQ ID NO:5. Figure 8. Western blot analysis of several pneumococcal whole cell lysate with polyclonal anti--r2 0 kDa sera. Molecular weight markers were run in lane 1; recombinant 20 kDa polypeptide from pDF 122 was run in lane 2; 15 recombinant 92 kDa polypeptide from Type 7 was run in lane 3; lane 4 was a blank; CP1200 whole cell lysate was run in lane 5; Type 3 whole cell lysate was run in lane 6; and Type 7 whole cell lysate was run in lane 7. The antisera recognizes the recombinant polypeptides of approximately 20 kDa and approximately 92 kDa, but only recognized the larger polypeptide in whole cell 20 lysates. Figure 9. Autoradiogram showing degradation of biotinylated C3 by 20 kDa and 92 kDa polypeptides of the present invention. Figure 10. Coomassie Blue-Stained 7.5% SDS-PAGE analysis of C3 degradation by the 20 kDa (Lane A8) and the 92 kDa (Lane C8) polypeptides of 25 the present invention. Figure 11 is a chart which shows the survival of CBA/CAHN xid/J mice immunized SC (subcutaneous) with r79 kDa protein adjuvanted with MPL and challenged IN (intranasal) with S. pneumoniae Type 3. Figure 12 is a SDS-PAGE gel described in Example 8. 30 WO 00/17370 PCT/US99/22362 9 Detailed Description of the Preferred Embodiments The present invention relates to the identification and isolation of a human complement C3 degrading polypeptide fragment of a larger polypeptide of about 75 kD to about 95 kD. This fragment has a molecular weight of about 5 20 kDa (± 5 kDa) on a 10% SDS-PAGE gel. It also relates to nucleic acids encoding C3 degrading polypeptides. It has been observed that exponentially growing cultures of pneumococci from several serotypes were able to first degrade the p-chain then degrade the a. chain of C3 without producing defined C3 cleavage fragments (Angel, et al. J. 10 Infect. Dis. 170:600-608, 1994). This pattern of degradation without cleavage differs substantially from that of other microbial products such as the elastase enzyme of Pseudomonas aeruginosa and the cysteine proteinase of Entamoeba histolytica. The term "degrade" is used herein to refer to the removal of amino acids 15 from proteinaceous molecules, generating peptides or polypeptides. The polypeptide of this invention degrade C3 without generating the cleavage fragments known as C3b, iC3b, or C3d. There is at least some preference of the C3-degrading polypeptides of this invention for C3 in that, for example, the C3 degrading polypeptide does not appear to degrade other proteins, such as 20 albumin. A C3-degrading polypeptide of about 20 kDa was isolated from a library of insertionally interrupted pneumococcal genes by identifying those clones that had decreased C3 degrading activity as compared to wild type S. pneumoniae.An exemplary assay for assessing C3-degrading activity of clones is provided in 25 Example 1. Clones with decreased C3-degrading activity were identified and a 546 bp SmaI insert was selected, based on the sequence of the clones that had demonstrated decreased C3-degrading activity. This SmaI fragment was used to probe an S. pneumoniae library made from strain CP1200. Positive clones from the S. pneumoniae library that hybridized to the SmaI fragment were isolated and 30 the open reading frame of the gene associated with C3-degrading activity was identified. The following oligonucleotide (SEQ ID NO:10), which has sequence identify with a portion of PspA, was used te -,oafirm, by differential WO 00/17370 PCT/US99/22362 10 hybridization, that the gene encoding the C3-degrading protinease was distinct from the gene encoding PspA. SEQ ID NO:10 5 GAAAACAATAATGTAGAAGACTACTTTAAAGAAGGTTAGA An open reading frame of a 20 kDa polypeptide spans an area of approximately 500 base pairs (SEQ ID NO:1) predicting a polypeptide of molecular weight of about 20 kDa (+/- 5 kDa) or about 168 amino acids (SEQ 10 ID NO:2). An exemplary gene sequence encoding a C3-degrading polypeptide is provided in Figure 1 as SEQ ID NO:1 and an amino acid sequence of the polypeptide is provided in Figure 2 as SEQ ID NO:2. Figure 3 combines a preferred gene sequence with a corresponding preferred translated polypeptide as SEQ ID NOS:1-3. 15 Using SEQ ID NO:2, the amino acid sequence of the approximately 20 kDa polypeptide, was determined to be unrelated to other polypeptides in the GenBank or Swiss Prot databases. The predicted polypeptide encompasses a proline-rich sequence characteristic of membrane domains in prokaryotes, particularly between amino acids 80-108 suggesting that the polypeptide is 20 expressed at the surface. The amino acid sequence exhibits no apparent choline binding repeats. Electrophoresis of pneumococcal lysates and supernatants from cultures of CP 1200 on SDS-PAGE gels impregnated with C3 identified a lytic band at about 20 kDa (+ 5 kDa) in both supernatants and lysates, confirming that a polypeptide of a size predicted by SEQ ID NO:2 had C3-degrading activity 25 (see Example 2). As provided in Example 3, the gene encoding the 20 kDa C3 degrading polypeptide is conserved in at least two dozen pneumococcal isolates representing five serotypes (serotypes 1, 3, 4, 14, and 19F). The nucleotide sequence encoding the C3-degrading polypeptide of this invention was inserted into a gene expression vector for expression in E. coli. 30 Recombinant C3-degrading polypeptide was isolated as described in the examples. Those of ordinary skill in the art recognize that, given a particular gene sequence such as that - n-ided in 'IST( ID NO:1, there are a variety of WO 00/17370 PCT/US99/22362 11 expression vectors that could be used to express the gene. Further, there are a variety of methods known in the art that could be used to produce and isolate the recombinant polypeptide of this invention and those of ordinary skill in the art also recognize that the C3 degrading assay of this invention will determine 5 whether or not a particular expression system, in addition to those expression systems provided in the examples, is functioning, without requiring undue experimentation. A variety of molecular and immunological techniques can be found in basic technical texts such as those of Sambrook et al. (Molecular Cloning, A Laboratory Manual, 1989 Cold Spring Harbor Laboratory Press, 10 Cold Spring Harbor, NY) and Harlow et al. (Antibodies; A Laboratory Manual. Cold Spring Harbor, NY; Cold Spring Harbor Laboratory Press, 1988). The polynucleotide encoding the C3 degrading polypeptide of this invention was identified using a plasmid library made with pneumococcal genomic DNA fragments from strain CP1200. Although there are a variety of 15 methods known for obtaining a plasmid library, in a preferred strategy, a plasmid library was constructed with Sau 3A digested pneumococcal genomic DNA fragments (0.5 -4.0 kb) from pneumococcal strain CP 1200 (obtained from D.A. Morrison, University of Illinois, Champagne-Urbana, Illinois and described in Havarstein LF, et al. Proc. Natl. Acad. Sci. (USA) 1995;92:11140-11144) and 20 inserted into the Bam HI site of the integrative shuttle vector pVA 891 (ermr, cmr; has origin of replication for E. coli). This library was transformed into an E. coli DH5cx MCR strain by electroporation. Plasmid extractions of some randomly selected E. coli transformants revealed that all of them contained recombinant plasmids. 25 Plasmid library DNA can be extracted from the E. coli transformants and used to transform the CP 1200 parent pneumococcal strain using insertional mutagenesis by homologous recombination. The pneumococcal strain CP 1200 cells can be made competent using a pH shift with HCl procedure in CTM medium. The competent cells are frozen at 30 -70*C in small aliquots until needed. The isolated polypeptide of this invention can be incubated with human complement C3 for 4 boK, or longer 3 7*C in the presence of PBS to detect WO 00/17370 PCT/US99/22362 12 C3 degradation. Control samples without the isolated pneumococcal polypeptide are used as controls for comparative purposes. The polypeptides of this invention have an apparent molecular weight on a 10% SDS-polyacrylamide gel of either about 15 kDa to about 25 kDa; and 5 preferably about 20 kDa; or about 75 kDa to about 95 kDa; and preferably about 92 kDa. Exemplary polypeptides sequences are provided by SEQ ID NO: 2 and SEQ ID NO:5. Those of ordinary skill in the art will recognize that some variability in amino acid sequence is expected and that this variability should not detract from the scope of this invention. For example, conserved mutations do 10 not detract from this invention nor do variations in amino acid sequence identity of less than about 80% amino acid sequence identity and preferably less than about 90% amino acid sequence identity where the polypeptide is capable of degrading human complement protein C3, and particularly where the polypeptide is isolated or originally obtained from an S. pneumoniae bacterium. 15 Proteins and fragments thereof (all referred to as polypeptides) are also within the scope of the present invention, particularly if they are capable of degrading human complement protein C3. Some nucleic acid sequence variability is expected among pneumococcal strains and serotypes as is some amino acid variability. Conserved amino acid 20 substitutions are known in the art and include, for example, amino acid substitutions using other members from the same class to which the amino acid belongs. For example, the nonpolar amino acids include alanine, leucine, isoleucine, valine, proline, phenylalanine, and tryptophan. The polar neutral amino acids include glycine, serine, threonine, cysteine, tyrosine, asparagine and 25 glutamine. The positively charged (basic) amino acids include arginine, lysine and histidine. The negatively charged (acidic) amino acids include aspartic acid and glutamic acid. Such alterations are not expected to affect apparent molecular weight as determined by polyacrylamide gel electrophoresis or isoelectric point. Particularly preferred conservative substitutions include, but 30 are not limited to, Lys for Arg and vice verse to maintain a positive charge; Glu for Asp and vice versa to maintain a negative charge; Ser for Thr so that a free -OH is maintained; and Gln for Asn to maintain a free NH 2
.
WO 00/17370 PCTIUS99/22362 13 Preferred polypeptides of this invention includes polypeptides with the amino acid sequence of SEQ ID NO:2 or SEQ ID NO:5. Other polypeptides include those degrading human complement polypeptide C3 and having nucleic acid encoding the polypeptide that hybridizes to SEQ ID NO:1 or SEQ ID NO:4 5 under highly stringent hybridization conditions such as 6XSSC, 5X Denhardt, 0.5% SDS (sodium dodecyl sulfate), and 100 ptg/ml fragmented and denatured salmon sperm DNA hybridized overnight at 65*C and washed in 2X SSC, 0.1% SDS one time at room temperature for about 10 minutes followed by one time at, 65*C for about 15 minutes followed by at least one wash in 0.2XSSC, 0.1% SDS 10 at room temperature for at least 3-5 minutes are also contemplated in this invention. Typically, an SSC solution contains sodium chloride, sodium citrate, and water to prepare a stock solution. The polypeptides of this invention can be isolated or prepared as recombinant polypeptides. That is, nucleic acid encoding a protein, or a portion 15 thereof, can be incorporated into an expression vector or incorporated into a chromosome of a cell to express the polypeptide in the cell. The polypeptide can be purified from a bacterium or another cell, preferably a eukaryotic cell and more preferably an animal cell. Alternatively, the polypeptide can be isolated from a cell expressing the polypeptide, such as a S. pneumoniae cell. Thus, 20 proteins, peptides, or polypeptides are all considered within the scope of this invention when the term "polypeptide" is used. The polypeptides are preferably at least 15 amino acids in length and preferred polypeptides have at least 15 sequential amino acids from SEQ ID NO:2 or SEQ ID NO:5. Nucleic acid encoding the about 15 kDa to about 20 kDa polypeptide and 25 the about 75 kD to about 95 kD polypeptide are also part of this invention. SEQ ID NOS: 1 and 4 are preferred nucleic acid molecules encoding a C3-degrading polypeptide. Those of ordinary skill in the art will recognize that some substitution will not alter the C3 -degrading polypeptide sequence to an extent that the character or nature of the C3-degrading polypeptide is substantially 30 altered. For example, nucleic acid with an identity of at least 80% to SEQ ID NO:1 is contemplated in this invention. A method for determining whether a particular nucleic sequence .iis within the scope of this invention is to WO 00/17370 PCT/US99/22362 14 consider whether or not a particular nucleic acid sequence encodes a C3 degrading polypeptide and has a nucleic acid identity of at least 80% as compared with SEQ ID NO: 1 or SEQ ID NO:4. Other nucleic acid sequences encoding the C3 polypeptide include nucleic acid encoding the C3 polypeptide 5 where the C3 polypeptide has the same sequence or at least a 90% sequence identity with SEQ ID NO:2 or SEQ ID NO:5 but which includes degeneracy with respect to the nucleic acid sequence. A degenerate codon means that a different three letter codon is used to specify the same amino acid. For example, it is well known in the art that the following RNA codons (and therefore, the 10 corresponding DNA codons, with a T substituted for a U) can be used interchangeably to code for each specific amino acid: Phenylalanine (Phe or F) UUU, UUC, UUA or UUG Leucine (Leu or L) CUU, CUC, CUA or CUG Isoleucine (Ile or I) AUU, AUC or AUA 15 Methionine (Met or M) AUG Valine (Val or V) GUU, GUC, GUA, GUG Serine (Ser or S) AGU or AGC Proline (Pro or P) CCU, CCC, CCA, CCG Threonine (Thr or T) ACU, ACC, ACA, ACG 20 Alanine (Ala or A) GCU,GCGGCA,GCC Tryptophan (Trp) UGG Tyrosine (Tyr or Y) UAU or UAC Histidine (His or H) CAU or CAC Glutamine (Gln or Q) CAA or CAG 25 Asparagine (Asn or N) AAU or AAC Lysine (Lys or K) AAA or AAG Aspartic Acid (Asp or D) GAU or GAC Glutamic Acid (Glu or E) GAA or GAG Cysteine (Cys or C) UGU or UGC 30 Arginine (Arg or R) AGA or AGG Glycine (Gly or G) GGU or GGC or GGA or GGG .rmindtio7 -Cdon UAA, UAG or UGA WO 00/17370 PCTIUS99/22362 15 Further, a particular DNA sequence can be modified to employ the codons preferred for a particular cell type. For example, the preferred codon usage for E. coli is known, as are preferred codons for animals including humans. These changes are known to those of ordinary skill in the art and 5 therefore these gene sequences are considered part of this invention. Other nucleic acid sequences include at least 15, and preferably, at least 30 nucleic acids in length from SEQ ID NO:1 or SEQ ID NO:4 or other nucleic acid fragments of at least 15, and preferably at least 30 nucleic acids in length where these fragments hybridize to SEQ ID NO: 1 or SEQ ID NO:4 under highly 10 stringent hybridization conditions such as 6XSSC, 5X Denhardt, 0.5% SDS, and 100 tg/ml fragmented and denatured salmon sperm DNA hybridized overnight at 65*C and washed in 2X SSC, 0.1% SDS one time at room temperature for about 10 minutes followed by one time at, 65*C for about 15 minutes followed by at least one wash in 0.2XSSC, 0.1% SDS at room temperature for at least 3-5 15 minutes. The nucleic acid molecules of this invention can encode all, none (i.e., fragments that cannot be transcribed, fragments that include regulatory portions of the gene, or the like), or a portion of SEQ ID NO:2 or SEQ ID NO:5 and preferably containing a contiguous nucleic acid fragment that encodes at least 20 nine amino acids from SEQ ID NO:2 or SEQ ID NO:5. Because nucleic acid molecues encoding a portion of a C3 degrading polypeptide are contemplated in this invention, it will be understood that not all of the nucleic acid molecules will encode a protein or peptide or polypeptide with C3 degrading activity. Further, the nucleic acid of this invention can be mutated to remove or otherwise 25 inactivate the C3 degrading activity of this polypeptide. Therefore, nucleic acid molecules that encode polypeptides without C3 degrading activity that meet the hybridization requirements described above are also contemplated. Methods for mutating or otherwise altering nucleic acid sequences are well described in the art and the production of an immunogenic, but enzymatically inactive 30 polypeptide can be tested for therapeutic utility. The nucleic acid molecuks of this invention can be incorporated into nucleic q' vectors o- -.. ably incorporated into host genomes to produce WO 00/17370 PCT/US99/22362 16 recombinant polypeptides including recombinant chimeric polypeptides. In one embodiment, the C3-degrading polypeptide is encoded by a gene in a vector and the vector is in a cell. Preferably, the cell is a prokaryotic cell such as a bacterium. The genes and gene fragments can exist as the fusion of all or a 5 portion of the gene with another gene and the C3-degrading polypeptide can exist as a fusion protein of one or more proteins where the fusion protein is expressed as a single protein. A variety of nucleic acid vectors of this invention are known in the art and include a number of commercially available expression plasmids or viral vectors. The use of these vectors is well within the scope of 10 what is ordinary skill in the art. Exemplary vectors are employed in the examples, but should not be construed as limiting on the scope of this invention. This invention also relates to antibodies capable of binding (typically specifically binding) to polypeptides of about 15 kDa to about 25 kDa; and preferably about 20 kDa; and about 75 kDa to about 95 kDa; and preferably 15 about 92 kDa, from S. pneumoniae and preferably where the polypeptides are capable of degrading human complement C3. Polyclonal or monoclonal antibodies can be prepared to all or part of the polypeptides of the invention Methods for preparing antibodies to polypeptides are well known and well described, for example, by Harlow et al., (Antibodies; A Laboratory Manual. 20 Cold Spring Harbor, NY; Cold Spring Harbor Laboratory Press, 1988). In a preferred example, the antibodies can be human derived, rat derived, mouse derived, goat derived, chicken derived, or rabbit derived. Polypeptide-binding antibody fragments and chimeric fragments are also known and are within the scope of this invention. 25 The invention also relates to the use of immune stimulating compositions. The term "immune stimulating" or "immune system stimulating" composition refers to protein, peptide, or polypeptide compositions according to the invention that activate at least one cell type of the immune system in a subject, such as a mammal. Preferably, the immune stimulating composition 30 provides an immunizing response or prophylactic benefit in a normal, i.e., uninfected subject, typically a vaccine. However, any measurable immune response is beneficial to the subject in a therapy application or protocol.
WO 00/17370 PCT/US99/22362 17 Preferred activated cells of the immune system include phagocytic cells such as neutrophils or macrophages, T cells, B cells, epithelial cells and endothelial cells. Immune stimulating compositions comprising the peptides, polypeptides or proteins of the invention can be used to produce antibody in an animal such as 5 a rat, mouse, goat, chicken, rabbit, or a human or an animal model for studying S. pneumoniae infection. Preferred immune stimulating compositions include an immune stimulating amount, e.g, a therapeutically effective amount, of at least one peptide or polypeptide including at least 15 amino acids from the C3 degrading polypeptide. 10 The term "vaccine" refers to a composition for immunization. This process can include the administration of a protein, peptide, polypeptide, antigen, nucleic acid sequence or complementary sequence, e.g., anti-sense, or antibody, or suspensions thereof, wherein upon administration, the molecule will produce active immunity and provide protection against an S. pneumoniae 15 infection or colonization. Typically, such vaccines are prepared as injectables, either as liquid solutions or suspensions. Solid forms suitable for solution in, or suspension in, liquid prior to injection may also be prepared. The vaccine preparation may optionally be emulsified, or encapsulated in liposomes. The immune stimulating composition (such as a vaccine) can further 20 include other polypeptides in a pharmaceutically acceptable buffer or carrier, such as PBS (phosphate buffer saline) or another buffer recognized in the art as suitable and safe for introduction of polypeptides into a host to stimulate the immune system. The immune stimulating compositions can also include other immune system stimulating polypeptides such as adjuvants or immune 25 stimulating proteins, peptides, or polypeptides from S. pneumoniae or other organisms. For example, a cocktail of peptides or polypeptides may be most useful for controlling S. pneumoniae infection. Preferably one or more of the polypeptides, or fragments thereof, of this invention are used in a vaccine preparation to protect against or limit S. pneumoniae colonization or the 30 pathogenic consequences of S. pneumoniae colonization. A "therapeutically effo tive amount," as used herein, refers to that amorv'. Uiat is effe:a Kve for production of a desired result. This amount varies WO 00/17370 PCT/US99/22362 18 depending upon the health and physical condition of a subject's immune system, i.e., to synthesize antibodies, the degree of protection desired, the formulation prepared and other relevant factors. It is expected that the amount will fall in a relatively broad range that can be determined through routine trials. 5 The active immune stimulating ingredients are often mixed with excipients or diluents that are pharmaceutically acceptable as carriers and compatible with the active ingredient. The term "pharmaceutically acceptable carrier" refers to a carrier(s) that is "acceptable" in the sense of being compatible with the other ingredients of a composition and not deleterious to the recipient 10 thereof. Suitable excipients are, for example, water, saline, dextrose, glycerol, ethanol, or the like and combinations thereof. In addition, if desired, the immune stimulating composition (including vaccine) may contain minor amounts of auxiliary substances such as wetting or emulsifying agents, pH buffering agents, and/or adjuvants which enhance the effectiveness of the immune stimulating 15 compostion. Examples of adjuvants or carriers that may be effective include but are not limited to: aluminum hydroxide, N-acetyl-muramyl-L-threonyl-D isoglutamine (thr-MDP); N-acetyl-nor-muramyl-L-alanyl-D-isoglutamine (CGP 11637, referred to as nor-MDP), N-acetylmuramyl-L-alanyl-D-isoglutaminyl-L 20 alanine-2-(l'-2'-dipalmitoyl-sn-glycero-3-hydroxyphosphoryloxy)-ethylamine (CGP 19835A, referred to as MTP-PE), and RIBI, which contains three components extracted from bacteria, monophosphoryl lipid A, trehalose dimycolate and cell wall skeleton (MPL + TDM + CWS) in a 2% squalene/Tween 80 emulsion. 25 This invention also relates to a method for inhibiting Streptococcus pneumoniae-mediated C3 degradation comprising contacting a Streptococcus pneumonie bacterium with a polypeptide, such as an antibody or another polypeptide that is capable of binding to an isolated polypeptide (typically, at least a portion thereof) of about 15 kDa to about 25 kDa, or about 75 kDa to 30 about 95 kDa, from Streptococcus pneumoniae. The protein capable of binding to an isolated polypeptide of about 15 kDa to about 25 kDa, or about 75 kDa to ab- 95 kDa ' : be an antibody or a fragment thereof, or the protein can be a WO 00/17370 PCT/US99/22362 19 chimeric protein that includes the antibody binding domain, such as a variable domain, from antibody that is capable of specifically recognizing an isolated polypeptide of about 15 kDa to about 25 kDa, or about 75 kDa to about 95 kDa, from Streptococcus pneumoniae having C3 degrading activity. 5 The isolated S. pneumoniae polypeptide of this invention can be isolated, and optionally purified, and the isolated polypeptide or immunogenic fragments thereof can be used to produce an immunologic response, including, in one example, an antibody response in a human or an experimental animal. Polypeptides without C3 degrading ability can be tested for their ability to limit 10 the effects of S. pneumoniae infection. Similarly, the polypeptides of this invention can be modified, such as through mutation to interrupt or inactivate the C3 degrading activity of the polypeptides. Antibody capable of inhibiting the C3-degrading activity of the polypeptides of this invention may be used as a strategy for preventing C3 degradation and for promoting clearance of S. 15 pneumoniae through the opsonic pathway. Isolated polypeptides can be used in assays to detect antibody to S. pneumoniae or as part of a vaccine or a multi valent or multiple protein, peptide, or polypeptide-containing vaccine for S. pneumoniae therapy. Thus, the term "treatment," as used herein, refers to prophylaxis and/or 20 therapy of either normal mammalian subjects or mammalian subjects colonized with, diagnosed with, or exhibiting characteristics or symptoms of various S. pneumoniae infections. The term "therapy" refers to providing a therapeutic effect to a mammalian subject such that the subject exhibits few or no symptoms of a pneumococcal infection or other related disease. Such treatment can be 25 accomplished by administration of nucleic acid molecules (sense or antisense), proteins, peptides or polypeptides or antibodies of the instant invention. It is further contemplated that the polypeptides of this invention can be surface expressed on vertebrate cells and used to degrade C3, for example, where complement deposition (or activation) becomes a problem, such as in 30 xenotransplantation or in complement-mediated glomerulonephritis. For example, the entire pneurnococcal polypeptide, a recombinant polypeptide, or a ri. Lion of ei- ., can be incorporated into xenotransplant cells and expressed as WO 00/17370 PCTIUS99/22362 20 a surface polypeptide or as a secreted polypeptide to prevent or minimize complement deposition (and/or complement-mediated inflammation). Another specific aspect of the present invention relates to using a vaccine vector expressing an isolated protein, and peptides or polypeptides therefrom. 5 Accordingly, in a further aspect this invention provides a method of inducing an immune response in a mammal, which comprises providing to a mammal a vaccine vector expressing at least one, or a mixture of an isolated protein and/or peptide or polypeptide of the invention. The protein and peptides or polypeptides of the present invention can be delivered to the mammal using a 10 live vaccine vector, in particular using live recombinant bacteria, viruses or other live agents, containing the genetic material necessary for the expression of the protein and/or peptides or polypeptides as a foreign polypeptide. Particularly, bacteria that colonizes the gastrointestinal tract, such as Salmonella, Shigella, Yersinia, Vibrio, Escherichia and BCG have been developed as vaccine vectors, 15 and these and other examples are discuessed by J. Holmgren et al., Immunobiol., 184, 157-179 (1992) and J. McGhee et al., Vaccine, 10, 75-88 (1992). An additional embodiment of the present invention relates to a method of inducing an immune response in a subject, e.g,. mammal, comprising administering to the subject an amount of a DNA molecule encoding an isolated 20 protein and/or peptide or polypeptide therefrom of this invention, optionally with a transfection-facilitating agent, where the protein and/or peptides or polypeptides retain immunogenicity and, when incorporated into an immune stimulating composition, e.g, vaccine, and administered to a human, provides protection without inducing enhanced disease upon subsequent infection of the 25 human with S. pneumoniae pathogen. Transfection-facilitating agents are known in the art. It is further contemplated that the antisense sequence of the gene encoding the about 15 kDa to about 25 kDa polypeptide, and the about 75 kDa to about 95 kDa polypeptide may be used as a vaccine or as a therapeutic treatment 30 for pneumococcal infection. Antisense DNA is defined as a non-coding sequence that is com'pleentary, i.e., a complementary strand, to all or a portion of SEQ Tr N-O:1 or SEQ ID NO:4. For example, the antisense sequence for 5'- WO 00/17370 PCT/US99/22362 21 ATGTCAAGC-3' is 3'-TACAGTTCG-5'. Delivery of antisense sequence or oligonuclotides into an animal may result in the production of antibody by the animal or in the incorporation of the sequence into living bacteria or other cells whereby transcription and/or translation of all or a portion of the 92 kDa gene 5 product is inhibited. Introduction of an antisense nucleic acid sequence can be accomplished, for example, by loading the antisense nucleic acid into a suitable carrier, such as a liposome, for introduction into pneumococci or infected cells. Typically, an antisense nucleic acid sequence having eight or more nucleotides is capable of 10 binding to the bacterial nucleic acid or bacterial messenger RNA. The antisense nucleic acid sequence, typically contains at least about 15 nucleotides, preferably at least about 30 nucleotides or more nucleotides to provide necessary stability of a hybridization product of bacterial nucleic acid or bacterial messenger RNA. Introduction of the sequences preferably inhibit the transcription or translation of 15 at least one endongenous S. pneumoniae nucleic acid sequence. Methods for loading antisense nucleic acid is known in the art as exemplified by U.S. Patent 4,242,046. The present invention also provides nucleic acid having an open reading frame of 2478 bases (SEQ ID NO:4) that encompasses the open reading frame of 20 a nucleic acid sequence (SEQ ID NO:1) that encodes a polypeptide that has a molecular weight of about 20 kDa (SEQ ID NO:2). The 20 kDa polypeptide, described herein, is further characterized as a C3-degrading polypeptide. The larger open reading frame, e.g., 2163 bp (SEQ ID NO:4), encodes for a putative polypeptide of about 92 kDa (SEQ ID NO:5). 25 All references and publications cited herein are expressly incorporated by reference into this disclosure. There are a variety of alternative techniques and procedures available to those of skill in the art which would similarly permit one to successfully perform the intended invention in view of the present disclosure. It will be appreciated by those skilled in the art that while the invention has been 30 described above in connection with particular embodiments and examples, the invention is not necessarily so limited and that numerous other embodiments, examoic -, uses, modifications and departures from the embodiments, examples WO 00/17370 PCT/US99/22362 22 and uses may be made without departing from the inventive scope of this application. 5 Example 1 Identification of Insertional Mutants with Reduced C3-Degrading Activity Insertional mutants were received from Dr. Elaine Tuomanen, (Rockefeller Inst., New York, New York). The clones with insertions were 10 tested in an assay to detect reduced C3-degrading activity. 137 clones were tested by growing the cells in Todd Hewitt broth overnight at room temperature in microtitre plates. The cells were diluted 1:10 in synthetic medium for pneumococci (see Sicard A. M., Genetics 50:31-44, 1984) and the remainder of the cells were frozen in the microtiter plate. Either 63 ng or 83 ng of C3 15 (purified from human plasma according to the method of Tack et al., Meth. Enzymol. 80:64-101, 1984) per 100 pl of medium containing 1 mg/ml of 0.1% BSA in phosphate buffered saline (PBS) was added to about 200 pL of diluted cells. The cells were incubated at 37'C for 4 hrs. One hundred pl of the mixture was added to ELISA plates and incubated overnight at 4*C. The plates were 20 washed three times with wash buffer and the wells were filled with 0.05% Tween 20 in PBS with five minute incubations between the washes. One hundred pl of antibody to C3 (polyclonal horse-radish peroxidase-conjugated goat antibody specific to human C3-IgG fraction, ICN Cappel, Costa Mesa, CA) was diluted 1:1200 with 3% BSA in PBS. The ELISA plate was incubated at 25 37'C for about 30 minutes to 1 hr in the dark and washed with wash buffer as above. The assay was developed using 12 mg of OPD in 30 ml of 0.1M sodium citrate buffer with 12 pl of 30% hydrogen peroxide. Assay results were determined by optical density readings at 490 nm on an ELISA plate reader. Each clone was tested four times. Nineteen clones were selected that had 30 less than 40% C3 degradation as compared to nonmutated controls. These 19 clones were screened 6 times by the assay described above and from these resul-1 o clones were selected with less than 30% C3-degrading activity as WO 00/17370 PCT/US99/22362 23 compared to controls. These 6 clones were screened eleven times each and the two clones with the lowest C3-degrading activity were selected for further study. A partial sequence of one of the clones was received and a SmaI fragment of 546 bp was labeled with 32 P by random primer labeling (kit 5 available from Stratagene, La Jolla, CA). The 546bp SmaI fragment from SEQ ID NO: 1 was hybridized to EcoR1 and KpnI digests of numerous pneumococcal strains on Southern blots. This same fragment was also used to screen a library of Sau3A fragments of genomic DNA from S. pneumoniae strain CP1200. A 3.5 kb insert was identified from the CP1200 library. The insert was 10 sequenced and an open reading frame of 492 base pairs, including the stop codon, was identified. The open reading frame coded for a polypeptide of 168 amino acids and a predicted molecular weight of about 18,500 daltons. PCR primers were constructed to amplify the open reading frame; the 5' PCR primer incorporated a BamHI site; the 3' primer incorporated a PstI site. 15 The amplified insert was ligated in frame to a His-Tagged E. coli expression vector pQE30 (Qiagen, San Diego, CA). The resulting plasmid was used to transform E. coli strain BL21 (Novagen, Madison, WI) containing the lac repressor plasmid pREP4 (Qiagen). E. coli cultures were induced to express the His-Tagged polypeptide and the polypeptide was column purified with Ni-NTA 20 resin (Qiagen). The purified polypeptide was confirmed by SDS-PAGE gel. Example 2 Identification of a 20kDa C3-Degrading Polypeptide To determine the C3-degrading capability of the 20 kDa polypeptide, 0.5 25 mg/ml of C3 (prepared according to Tack et al., Meth. Enzymol. 80:64-101, 1984) was copolymerized in a sodium dodecyl sulfate (SDS) gel-containing 15% acrylamide (15% SDS-PAGE gel). Pneumococcal supernatants were obtained from cultures of S. pneumoniae strain CP1200 grown to exponential phase in Todd Hewitt broth; pneumococcal lysates were obtained by incubating 5 x 108 30 cells with 5% SDS for 30 minutes at room temperature. The lysate was concentrated 10 fold using a Centricon filtration device with a 10,000 mw cutoff (A -icon, Beverly, MA). The samples were not heated before electrophoresis.
WO 00/17370 PCT/US99/22362 24 Samples of supernatants and lysates were added to the 15% C3-containing SDS PAGE gels and electrophoresis was carried out at 4C at 150 V until the dye front ran out. The gel was washed successively with 50 ml of 2.5% Triton X 100 in water (2 times, 10 minutes), 2.5 % Triton X-100 in 50 mM Tris-HCl, pH 5 7.4 (2 times, 10 minutes), and 50 mm Tris-HCl, pH 7.4 (2 times, 10 minutes) to remove SDS. After washes, 50 ml of 50 mM Tris-HCl, pH 7.4, was poured into dishes containing the gels, and the dishes were covered and incubated at 37'C for 1.5 hour and overnight (about 16 hours). The gels were stained with Coomassie blue for 10 minutes and destained totally. 10 Two lytic bands were visualized, one of which was about 20 kDa in size, against the dark blue background in both lysates and supernatant. C3 degrading activities in the pneumococcal lysates were observed after a 1.5 hour incubation at 37 0 C, while C3 degrading activities in the Pn supernatant were observed after an overnight incubation. Therefore, C3 degrading activities appeared to be 15 mainly cell associated. Example 3 The gene encoding the 20 kD polypeptide is conserved in a number of S. pneumoniae strains. 20 DNA was obtained from a variety of S. pneumoniae strains (Clinical isolates of Type 1, Type 3, L002 and L003 (type 3), Type 4, Type 14 and Laboratory isolates CP1200, WU2, R6X, 6303,109,110, JY1 119, JY182, and JY53) and SEQ ID NO:3 was used as a probe to detect the presence of nucleic acid encoding the 20 kD polypeptide in DNA from these strains. Isolated 25 chromosomal DNA was digested with EcoRI and separated by electrophoresis. The DNA was transferred to a solid support and hybridized to end-labeled SEQ ID NO:3 under the hybridization and washing conditions of 6X SSC, 5X Denhart's, 0.5% SDS, 100 [tg/ml denatured fragmented salmon sperm DNA hybridized at 65 *C overnight and washed in 2X SSC, 1 time at room 30 temperature for 10 minutes and in 2X SSC, 0.1% SDS 1 time at 65*C for 15 minutes followed by two washes in 0.2X SSC, 0.1% SDS for 3 minutes each at som temperature.
WO 00/17370 PCT/US99/22362 25 Results indicated that SEQ ID NO:3 hybridized identically in each of the DNA samples tested indicating that the polypeptide appears to be conserved among strains. In some strains, the DNA encoding the 20 kDa C3-degrading polypeptide appears to be part of a larger open reading frame of 2478 bp that 5 putatively encodes a 92 kDa polypeptide. Example 4 Southern blot of S. pneumoniae DNA probe Five ug samples of genomic DNA were obtained from 11 strains ofS. 10 pneumoniae. Each sample was digested with the restriction enzyme Kpnl. The samples were subsequently loaded onto an agarose gel and resolved by electrophoresis. The samples contained in the gel were subsequently transferred to a Hybond-N+ membrane available from Amersham (Upsalla, Sweden) by capillary transfer. A 540 bp SmaI fragment from the open reading frame was 15 random primer labeled with P 32 using a "QuickPrime kit (Pharmacia, Piscathaway, NJ) and purified from non-incorporated nucleotides using NucTrap column (Stragene, La Jolla, CA) and hybridized. The hybridization conditions were 6XSSC, 5X Denhardt, 0.5% SDS, and 100 pig/ml fragmented and denatured salmon sperm DNA hybridized overnight 20 at 65*C and washed in 2X SSC, 0.1% SDS once at room temperature for about 10 minutes followed by 1 time at, 65*C for about 15 minutes followed by at least one wash in 0.2XSSC, 0.1% SDS at room temperature for at least 3-5 minutes. The blot demonstrated that the 20 kDa gene was present in all tested strains of S. pneumoniae. 25 Example 5 Two DNA primers were prepared from SEQ ID NO: 1 and utilized to amplify the nucleotide sequence encoding the 20 kDa polypeptide from S. pneumoniae (serotype 3) genomic DNA. The first primer, a 5'-primer, SEQ ID 30 NO:6, includes an ATG start codon of the 5' end of the nucleotide sequence, inserts a Nco 1 site, and had an Ala residue inserted after the ATG start codon to maintain a correct reading frame. The second primer, a 3'-primer TEQ ID WO 00/17370 PCT/US99/22362 26 NO:7, includes a termination codon at the 3' end of the nucleotide sequence and inserts a BamH1 site. 5'-GGGGG CCA TGG CC TCA AGC CTT TTA CGT GAA TTG-3'; 5 (SEQ ID NO:6) 5'-GGGGG GGA TCC CTA GCT ATA TGA GAT AAA CTT TCC TGC T-3'; (SEQ ID NO:7) 10 The two primers were synthesized on an Applied Biosystems 380A DNA synthesizer (Foster City, CA) using reagents purchased from Glen Research (Sterling, VA). Amplifications were performed utilizing a Perkin Elmer Thermocycler (ABI) according to the manufacturer's directions. The identified PCR product was ligated into the TA tailed PCR cloning vector PCR2. 1, 15 available from Invitrogen, Carlsbad, CA, and used to transform OneShot TopI OF' competent cells (Invitrogen). Kanamycin resistant transformants were screened by restriction enzyme analysis of plasmid DNA prepared by alkaline lysis. An approximately 500 bp insert fragment was identified and subsequently excised with restriction enzymes Neol and BamHl. The 500 bp fragment was 20 purified from a low melting agarose gel, and subsequently ligated into the Ncol BamHl sites of the T7 promoted expression vector pET 28a, available from Novagen ( Madison, WI). The ligation mixture was subsequently transformed into TopI OF'cells (Invitrogen), and the kanamycin resistant transformants were screened by 25 restriction enzyme analysis of plasmid DNA prepared by alkaline lysis. A recombinant plasmid (pLP505) was subsequently tranformed into BL21 (Novagen) cells and grown in SOB media supplemented with 30 pg/ml kanamycin. Cells were grown to an O.D.oo of 0.6, and were subsequently induced with 0.4mM IPTG (Boehringer Mannheim, Indianapolis, Indiana) for 2 30 4 hours. Whole cell lysates were prepared and electrophoresed on a 14% SDS PAGE gel. The gel was stained with Coomassie and the expression product was detected. The coomassie stained gel revealed a band between the 28 kDa and the WO 00/17370 PCT/US99/22362 27 18 kDa molecular weight markers, and was determined to be approximately 20 kDa. The DNA sequence of the insert in the recombinant pLP505 plasmid was obtained using the ABI 370A DNA sequencer. The DNA sequence was aligned 5 with the DNA sequence of SEQ ID NO: 1, using the Pustell DNA matrix plot feature of MacVector (Oxford Molecular Group, Campbell, CA). Alignment of the DNA sequence obtained from the pLP505 plasmid, SEQ ID NO: 1, and the S. pneumoniae (serotype 4) genome, revealed that the open reading frame (ORF) that codes for the 20 kDa polypeptide may be part of a larger ORF, i.e., a 2478 10 bp in the serotype 4 genome, that codes for a polypeptide with a predicted MW of approximately 92 kDa (SEQ ID NO: 4). DNA SEQ ID NO:4 encodes for a predicted amino acid sequence as shown in SEQ ID NO:5. The S. pneumoniae (serotype 4) genome sequence was obtained from The Institute for Genomic Research at www.tigr.org and/or through NCBI at 15 www.ncbi.nlm.nih.gov, using the ClustalW feature of MacVector, (Oxford Molecular Group, Campbell CA). A sequence comparison was made between the 20 kDa amino acid sequence (SEQ ID NO:2) and the predicted 92 kDa amino acid sequence (SEQ ID NO:5). Based upon the available genomic DNA (serotype 4) sequence, two 20 primers flanking the 2478 bp ORF were designed and subsequently synthesized using the ABI 380A DNA synthesizer (SEQ ID NOS:8 and 9). SEQ ID NO:8 was an S. pneumoniae 5'-primer having an inserted Ncol site and a "Glu" residue added after the ATG start codon to maintain a correct reading frame. SEQ ID NO:9, was an S. pneumoniae 3'-primer having an inserted HindIll site. 25 5'- CCC GGG CCA TGG CTA AAA TTA ATA AAA AAT ATC TAG -3'; (SEQ ID NO:8) 5'-CCG GGC AAG CTT TTA CTT ACT CTC CT-3'-; (SEQ ID NO:9) 30 An approximately 2400 bp DNA fragment was then amplified from the 4 different S. pneumoniae serotypes (serotype 3, 5, 6B and 7) resulting in 4 WO 00/17370 PCT/US99/22362 28 fragments. Each of the 4 fragments were subsequently ligated into the PCR cloning vector PCR2.1 (Invitrogen), and used to transform OneShot Top 1OF' cells (Invitrogen). Kanamycin resistant transformants were screened by restriction analysis of the plasmid DNA prepared by alkaline lysis. A 5 recombinant plasmid containing the serotype 7 PCR product was identified, e.g., pLP512. The DNA sequence was obtained from the serotype 7 clone using the ABI model 370A DNA sequencer. The DNA sequence was essentially identical to SEQ ID NO:4 and encoded a predicted amino acid sequence essentially identical to SEQ ID NO:5. 10 Example 6 Western blot detection of 92 kDa Polypeptide in Whole Pneumococci Recombinant approximately 20 kDa C3 degrading polypeptide was 15 purified from Escherichia coli strain BLR containing plasmid pDF122. Plasmid pDF 122 contains the polynucleotide shown in SEQ ID NO: 1 expressed under control of the T7 phage promoter system. The bacterial cells were grown to mid log phase in Hy-Soy/yeast Extract medium containing ampicillin to select for the plasmid. Expression of the recombinant polypeptide was induced by adding 20 IPTG to a concentration of 1mM and continuing incubation for an additional 3 hours. The bacterial cells were harvested by centrifugation and resuspended in Tris buffered saline, pH 7.2. Cells were mechanically lysed in a French Pressure cell and the insoluble material including inclusion bodies were pelleted in a centrifuge. The pellet was solubilized in 3 M Urea buffered with 100mM NaPO 4 , 25 pH 8.0 containing 0.1% Triton X-100. After pelleting and discarding insoluble material (centrifuged at ~100,000 x g), the soluble r 20kDa polypeptide was exchanged into 0.1% Zwittergent 3-12 (Calbiochem-Behmg) replacing the Urea and then into 100 mM NaPO 4 pH 8.0 replacing the detergent. SDS-PAGE analysis confirmed that the ~20 kDa material remained soluble. The His-tagged 30 recombinant polypeptide was dialyzed into 50 mM NaPO 4 buffer, pH 8.0 and absorbed onto a Ni column equilibrated with the same buffer. The column was sequentially washed with 50 mM NaPO 4 at pH 7.0, 6.6, and 5.5 until baseline absorbances (OD 280 ) were reached with each buffer. The bound ~r20 kDa WO 00/17370 PCT/US99/22362 29 polypeptide was eluted with 50 mM NaPO 4 , pH 4.5. The eluted polypeptide was approximately 90% homogeneous in SDS-PAGE analysis. This polypeptide was used to immunize Swiss-Webster mice. Five pg doses of the polypeptide were mixed with 50 tg of Monophosphoryl lipid A 5 (Ribi Immunochemicals) and injected intramuscularly into mice. Animals were immunized at weeks 0, 4, and 6 and exsangruinated at week 8. The sera were pooled together and found to contain high titered antisera against the immunogen. Pneumococcal strains CP1200, T3, and T7 were grown in Todd-Hewitt 10 broth containing yeast Extract and the cells pelleted by centrifugation. Pneumococcal cells were lysed in SDS-PAGE cracking buffer under reducing conditions by boiling for 5minutes. The lysates were loaded onto a 10% SDS PAGE gel and electrophoresed. Separated polypeptides were electroblotted onto Nitrocellulose and the filter blocked with 5% BLOTTO in phosphate buffered 15 saline, pH 7.4. The polyclonal antisera was diluted 1:2000 in BLOTTO and used to probe the separated polypeptides. Bound antibodies were detected with Alkaline phosphatase conjugated goat anti-mouse IgG. The Western Blot is shown in Figure 8 and described further in the brief description of the figures. 20 Example 7 Evidence of that the 20 kDa and 92 kDa Polypeptides Degrade C3 The gel shown in Figure 9 is a Western blot. This data were obtained by 25 incubating a 20 kDa polypeptide and a 92 kDa polypeptide with biotinylated and methylamine-treated C3 as shown in the table below. These polypeptides were expressed from a T7 vector. METHYLAMINE-TREATED C3: 500 pl of purified human C3 at concentration of 4.46 mg/ml (prepared according to the method of Tack et al., 30 Meth. Enzymol. 80:64-101, 1984) was incubated with 55 pl of 1 M methylamine
(CH
3
NH
2 ) in 0.1 M TRIS/0.01 M EDTA, pH 8.0 for 80 minutes at 37"C, then dialyzed overnight in 0.1 M TRIS/0.01 M EDTA, pH 8.0, at 4 0 C. The following day, the C3 was incubated again with 60 il of 1 M methylamine in 0.1 M WO 00/17370 PCT/US99/22362 30 TRIS/0.01 M EDTA for 80 minutes at 37'C, then dialyzed overnight in 50 mM NaHCO 3 at 4 0 C. BIOTINYLATION of METHYLAMINE-TREATED C3: 2 mg of methylamine-treated C3, prepared above, was incubated with 75 p1l of NSC 5 biotin (Pierce) made as 1 mg NSC biotin in 1 ml H 2 0 for 30 minutes at room temperature. The biotinylated C3 was dialyzed overnight in 50 mM NaHCO 3 , pH 8.0 at 4 "C. Reagents Tube A - 20 kDa Tube C - 92 kDa Polypeptide 34 [d 20 kDa polypeptide 100 pl 92 kDa polypeptide 5.6 x 10-9 moles 5.6 x 10-9 moles Biotinylated C3 3 pl C3 3 pl C3 71 x 1012 moles 71 x 1012 moles Buffer 63 pl 0.01% BSA/PBS 63 pl 0.01% BSA/PBS 10 Samples from Tubes A and C were removed after 66 hours of incubation, reduced by boiling for 2 minutes in reducing buffer with p mercaptoethanol, electrophoresed on 7.5% SDS-PAGE, and transferred to nitrocellulose paper for Western blotting. Western blotting was carried out for one hour according to 15 standard procedures (Tobin et al. PNAS USA 76:4350-4354, 1979). Membranes were incubated with horseradish-peroxidase-avidin (1:10,000 dilution) and developed with the Supersignal CL.-HRP Substrate System (Amersham) to detect biotinylated C3 fragments. In Figure 9 lane 1 is C3 alone (control), lanes 2 and 3 are the 20 and 92 20 kDa polypeptides, and lanes 4 and 5 are again C3 alone (controls). Along the right margin the position of the a-chain of C3, the p-chain of C3, and the C3 fragment present in the control samples are shown. The position of a C3 fragment in the 20 kDa digest and several fragments in the 92 kDa digest are identified. 25 The second experiment used the reagents of the first (expressed polypeptides, biotinylated C3, and buffer) in the s" proportier! as shown in WO 00/17370 PCT/US99/22362 31 the table above. C3 control samples were removed at time 0, 2 hours, 8 hours, and 24 hours. However, instead of doing a Western blot, the samples were reduced on 7.5% SDS-PAGE, reasoning that some additional degradation fragments might not be biotinylated and would therefore show up on a 5 Coomassie stained SDS-PAGE gel. Indeed, that is what was observed. Only the 20 (lane A8) and 92 (lane C8) kDa polypeptides were analyzed on this gel. The gel of Figure 10 shows along the right margin the position of the a-chain of C3 and the p-chain of C3, and the 92 kDa polypeptide in lane C8. In lane C8 are at least two fragments ranging in size from -90 kDa to 75 kDa. There are also 10 several fragments beneath the p-chain at 75 kDa. In lane A8 is a major degradation fragment just below the p-chain of C3. Thus, both the 92 kDa polypeptide in lane C8 and the 20 kDa polypeptide in lane A8 degrade C3. 15 Example 8 Preparation of recombinant 92 kDa protein and generation of poyclonal anitsera The insert in plasmid pLP512 (see Example 5) was excised with Ncol 20 and HindIII. A fragment of the expected size was purified from low melting point agarose, and subsequently ligated into the Nco 1- HindIII sites of the T7 promoted expression vector pET28a (Novagen, Madison, WI). The ligation mixture was subsequently transformed into Top 1OF' cells (Invitrogen) and the kanamycin resistant transformants were screened as 25 described previously in Example 5. A recombinant plasmid (pLP515) was subsequently transformed into BL21 cells (Novagen) and grown in SOB media supplemented with 30 pg/ml kanamycin. Cells were grown to an O.D. 600 of 0.6, and were subsequently induced with 0.4 mM IPTG (Boehringer Mannheim, Indianapolis, IN) for 2-4 hours. Whole cell lysates were prepared and 30 electrophoresed on a 10% SDS-PAGE gel. Coomassie staining of the gel revealed a new band of approximately 80 kDa as compared to a pre-induction sample.
WO 00/17370 PCT/US99/22362 32 Recombinant protein coded by the -92 kDa ORF was purified from E. coli strain BL21 (Novagen) containing the plasmid pLP515. Bacterial cells were grown to mid log phase in SOB medium containing 50 pig/ml kanamycin to select for the plasmid. Expresssion of the recombinant polypeptide was induced by addition 5 IPTG to 0.4 mM and continuing incubation for 3 hours. The bacterial cells were harvested by centrifugation and resuspended in Tris-Buffered Saline, pH7.2. Cells were mechanically lysed in a French Pressure Cell and the insoluble material including inclusion bodies were pelleted in a centrifuge at 7700 x g at 4 degrees for 10 minutes. The pellet containing the inclusion bodies was 10 resolubilized and the soluble protein was purified by ion exchange chromatography. Recombinant protein was used to generate polyclonal antibodies in mice. Briefly, 5 pig of protein was adjuvanted for each dose with 20 pg QS21 and injected subcutaneously into the necks of a 6-8 weeks Swiss Webster mice. The mice were bled and vaccinated at week 0, vaccinated at week 15 4, then bled and exsanguinated at week 6. 10 mice were vaccinated with the recombinant 92 kDa protein adjuvanted with QS21. Pooled sera were used at a 1:1000 dilution to examine whole cell lysates and concentrated culture supernatants from several serotypes of S. pneumoniae on a Western Blot. The sera reacted specifically to a protein in whole cell lysates and concentrated 20 culture supernatants whose molecular weight was approximately 90 kDa. Example 9 The chart of Figure 11 summarizes the results from an intranasal (IN) 25 challenge of CBA/CAHN xid/J mice vaccinated with r92 kDa protein, prepared as described in Example 8 (SEQ ID NO:5) adjuvanted with monophosphoryl lipid A (MPL). 10 mice per group were vaccinated subcutaneously in the neck region at weeks 0, 3,and 5, with either 5 jig each of 92 kDa adjuvanted with 50 jig MPL, 30 1 jig each of Type 3 capsule conjugated to the protein carrier CRM197 adjuvanted with 100 jig aluminum phosphate, or phosphate buffered saline (PBS) alone, in a sample volume of 10 il. CRM 197 is a genetically detoxified version of diptheria toxin. Each mouse was challenged in at week 7 with 1 x 106 WO 00/17370 PCT/US99/22362 33 cfu's of Type 3 S. pneumoniae in a 10 ptl sample volume. Nasal tissue was isolated 3 days after challenge and the number of type 3 S. pneumoniae colony forming units per gram of nasal tissue determined by plating on selective media. Type 3 is capsule isolated from S. pneumoniae serotype 3, and then conjugated 5 to protein carrier CRM 197, through reductive animation (see U.S. Patent No. 5, 360,897 for preparation of the Type 3 control; see U.S. Patent No. 5,614,382 for genetically detoxified version of ditheria toxin; see U.S.Patent 4,902,506 with regard to using CRM 197 as a carrier). The chart in Figure 11 shows that in this model, both the negative 10 controls, mice adjuvanted with MPL and niive mice at 6 weeks of age, had a survival rate of approximately 30% when challenged intranasally, while the positive control, the Type 3 conjugate adjuvanted with aluminum phosphate, offered 100% protection against death to the end of the study, approximately 14 days. When mice immunized with r92 kDa were challenged, 100% survived to 15 the end of the study, indicating that r92 kDa protein does offer protection against death from intranasal challenge by Type 3 S. pneumoniae. Example 10 METHODS 20 Recombinant 92 kDa (r92 kDa) polypeptide (SEQ ID NO:5) were incubated with purified human C3 for 2 hours, 6 hours, and 26 hours at 37*C in the following ratios: Tube A (Control) : C3 - 3pl [7.2x10-12 moles] PBS/0.01% bovine serum albumin (BSA) - 100 pl; Tube B: r92 kDa - 50 pl [5.6x10-10 moles] C3 - 3 pl 25 [7.2x10-12 moles] PBS/0.01% BSA - 50 pl. At each time point (2, 6, and 26 hours), 20 pl samples were removed from Tubes A and B reducing buffer was added, and the samples were boiled at 1 00*C for 2 minutes. After boiling, samples were electrophoresed on 7.5% SDS-PAGE under 30 reducing conditions. The SDS-PAGE gel was stained with Coomassie blue. The resultant gel is shown in Figure 12.
WO 00/17370 PCTIUS99/22362 34 Lane 1 - molecular weight standards (reading from top of gel: 200 kDa, 116 kDa, 97 kDa, 66 kDa, 45 kDa); Lanes 2 and 4 - 2 hour incubation; Lane 2 - C3 control (Tube A); Lane 4 - r92 kDa sample (Tube B); Lanes 5 and 7 - 6 hour 5 incubation; Lane 5 - C3 control (Tube A); Lane 7 - r92 kDa sample (Tube B); Lanes 8 and 10 - 26 hour incubation; Lane 8 - C3 control (Tube A); Lane 10 r92 kDa sample (Tube B). INTERPRETATION of GEL 10 The a-chain of C3 runs at about 115 kDa. The p-chain of C3 runs at about 75 kDa. These are marked on the gel. The band at about 66 kDa is albumin. Lanes 2 and 4 are the 2-hour incubation. Compared to Lane 2 (C3 control), Lane 4 shows cleavage of the C3 a-chain - new fragment at -97 kDa. Lanes 5 and 7 are the 6-hour incubation. There is the same new 97 kDa cleavage 15 fragment in Lane 7. Lanes 8 and 10 are the 26-hour incubation. Compared to Lane 8 (C3 control), Lane 10 shows continued cleavage of the a-chain. It will be appreciated by those skilled in the art that while the invention has been described above in connection with particular embodiments and 20 examples, the invention is not necessarily so limited and that numerous other embodiments, examples, uses, modifications and departures from the embodiments, examples and uses may be made without departing from the inventive scope of this application.
Claims (35)
1. An isolated polypeptide comprising an amino acid sequence; wherein the nucleic acid sequence encoding the amino acid sequence of the isolated polypeptide hybridizes under highly stringent hybridization conditions to at least a portion of either (a) the nucleotides in SEQ ID NO:1 or a complementary strand thereof, or (b) the nucleotides in SEQ ID NO:4 or a complementary strand thereof.
2. The polypeptide of claim 1 which is isolated from S. pneumoniae.
3. The polypeptide of claim 1 which is a recombinant polypeptide.
4. The polypeptide of claim 1 having a molecular weight of about 15 kDa to about 25 kDa.
5. The polypeptide of claim 1 having a molecular weight of about 75 kDa to about 95 kDa.
6. The polypeptide of claim 1 which degrades human complement protein C3.
7. The polypeptide of claim 1 comprising at least 15 sequential amino acids.
8. An isolated polypeptide comprising at least 15 sequential amino acids of SEQ ID NO:2 or SEQ ID NO:5.
9. An isolated polypeptide comprising SEQ ID NO:2 or SEQ ID NO:5. WO 00/17370 PCT/US99/22362 36
10. An immune system stimulating composition comprising an effective amount of the polypeptide of claim 1 and a therapeutically acceptable carrier.
11. The immune system stimulating composition of claim 10 wherein the polypeptide is isolated from S. pneumoniae.
12. The immune system stimulating composition of claim 11 further comprising at least one other immune system stimulating polypeptide isolated from S. pneumoniae.
13. The immune system stimulating composition of claim 10 wherein the polypeptide is effective to immunize or treat a mammalian subject against S. pneumoniae infection or colonization.
14. The immune system stimulating composition of claim 13 wherein the polypeptide is provided in an amount effective to provide a therapeutic effect to the mammalian subject.
15. An antibody capable of binding to the polypeptide of claim 1.
16. The antibody of claim 15 which is a monoclonal antibody.
17. The antibody of claim 16 which is obtained from a mouse, a rat, a goat, a chicken, a human, or a rabbit.
18. An isolated nucleic acid molecule which hybridizes under highly stringent hybridization conditions to at least a portion of either (a) the nucleotides in SEQ ID NO: 1 or a complementary strand thereof, or (b) the nucleotides in SEQ ID NO:4 or a complementary strand thereof.
19. The nucleic acid molecule of cim 18 isoltexI from S. pneumoniae. WO 00/17370 PCTIUS99/22362 37
20. The nucleic acid molecule of claim 19 which encodes a polypeptide that degrades human complement C3.
21. A vector comprising the nucleic acid molecule of claim 18.
22. A cell comprising the nucleic acid of claim 18.
23. The cell of claim 22 which is a bacterium or a eukaryotic cell.
24. An isolated nucleic acid molecule comprising the nucleic acid sequence of SEQ ID NO: 1 or its complementary strand or SEQ ID NO:4 or its complementary strand.
25. An RNA molecule transcribed by a double-stranded DNA sequence comprising SEQ ID NO: 1 or SEQ ID NO:4.
26. A method for producing an immune response to S. pneumoniae in a mammal, the method comprising administering to a mammal a composition comprising: (a) a therapeutically effective amount of the polypeptide of claim 1; and (b) a pharmaceutically acceptable carrier.
27. The method of claim 26 wherein the immune response is a B cell response, a T cell response, an epithelial cell response, or an endothelial cell response.
28. The method of claim 26 wherein the polypeptide is at least 15 amino acids in length. WO 00/17370 PCT/US99/22362 38
29. The method of claim 26 wherein the composition further comprises at least one other immune system stimulating polypeptide from S. pneumoniae.
30. A method for inhibiting S. pneumoniae-mediated C3 degradation, the method comprising contacting an S. pneumoniae bacterium with an antibody capable of binding to the polypeptide of claim 1.
31. A method for inhibiting C3-mediated inflammation and rejection in xenotransplantation, the method comprising expressing on the surface of an organ of an animal used in xenotransplantation the polypeptide of claim 1.
32. An isolated nucleic acid molecule having a nucleic acid sequence selected from the group consisting of SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, and SEQ ID NO:9.
33. An isolated polypeptide having at least 80% sequence identify to SEQ ID NO:2 or SEQ ID NO:5.
34. An isolated polypeptide of about 15 kDa to about 25 kDa from S. pneumoniae that degrades human complement protein C3.
35. An isolated polypeptide of about 75 kDa to about 95 kDa from S. pneumoniae that degrades human complement protein C3.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10173698P | 1998-09-24 | 1998-09-24 | |
US60101736 | 1998-09-24 | ||
US28309499A | 1999-03-31 | 1999-03-31 | |
US09283094 | 1999-03-31 | ||
PCT/US1999/022362 WO2000017370A1 (en) | 1998-09-24 | 1999-09-24 | HUMAN COMPLEMENT C3-DEGRADING POLYPEPTIDE FROM $i(STREPTOCOCCUS PNEUMONIAE) |
Publications (1)
Publication Number | Publication Date |
---|---|
AU6060899A true AU6060899A (en) | 2000-04-10 |
Family
ID=26798575
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU60608/99A Abandoned AU6060899A (en) | 1998-09-24 | 1999-09-24 | Human complement c3-degrading polypeptide from (streptococcus pneumoniae) |
Country Status (10)
Country | Link |
---|---|
EP (1) | EP1115875A1 (en) |
JP (1) | JP2002526082A (en) |
KR (1) | KR20010089280A (en) |
CN (1) | CN1352691A (en) |
AU (1) | AU6060899A (en) |
BR (1) | BR9914066A (en) |
CA (1) | CA2343931A1 (en) |
IL (1) | IL142017A0 (en) |
MX (1) | MXPA01003073A (en) |
WO (1) | WO2000017370A1 (en) |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE69737125T3 (en) * | 1996-10-31 | 2015-02-26 | Human Genome Sciences, Inc. | Streptococcus pneumoniae antigens and vaccines |
US6800744B1 (en) * | 1997-07-02 | 2004-10-05 | Genome Therapeutics Corporation | Nucleic acid and amino acid sequences relating to Streptococcus pneumoniae for diagnostics and therapeutics |
ATE422899T1 (en) | 1998-12-21 | 2009-03-15 | Medimmune Inc | STREPTOCOCCUS PNEUMONIAE PROTEINS AND IMMUNOGENIC FRAGMENTS FOR VACCINES |
EP1950302B1 (en) | 1998-12-23 | 2012-12-05 | ID Biomedical Corporation of Quebec | Streptococcus antigens |
TR200200633T2 (en) * | 1998-12-23 | 2002-06-21 | Shire Biochem Inc. | New streptococcus antigens |
US7128918B1 (en) | 1998-12-23 | 2006-10-31 | Id Biomedical Corporation | Streptococcus antigens |
US7074415B2 (en) | 2000-06-20 | 2006-07-11 | Id Biomedical Corporation | Streptococcus antigens |
CA2413450C (en) * | 2000-06-20 | 2014-02-18 | Shire Biochem Inc. | Streptococcus antigens |
GB0022742D0 (en) | 2000-09-15 | 2000-11-01 | Smithkline Beecham Biolog | Vaccine |
US7262024B2 (en) | 2001-12-20 | 2007-08-28 | Id Biomedical Corporation | Streptococcus antigens |
JP4768620B2 (en) * | 2003-05-15 | 2011-09-07 | ジェネンテック, インコーポレイテッド | Methods and compositions for the prevention and treatment of sepsis |
US20070184072A1 (en) | 2005-04-08 | 2007-08-09 | Wyeth | Multivalent pneumococcal polysaccharide-protein conjugate composition |
IL308456A (en) | 2005-04-08 | 2024-01-01 | Wyeth Llc | Multivalent pneumococcal polysacharide-protein conjugate composition |
US7955605B2 (en) | 2005-04-08 | 2011-06-07 | Wyeth Llc | Multivalent pneumococcal polysaccharide-protein conjugate composition |
US7709001B2 (en) | 2005-04-08 | 2010-05-04 | Wyeth Llc | Multivalent pneumococcal polysaccharide-protein conjugate composition |
US8008453B2 (en) | 2005-08-12 | 2011-08-30 | Amgen Inc. | Modified Fc molecules |
WO2007047995A2 (en) * | 2005-10-21 | 2007-04-26 | Catalyst Biosciences, Inc. | Modified proteases that inhibit complement activation |
TWI457133B (en) | 2005-12-13 | 2014-10-21 | Glaxosmithkline Biolog Sa | Novel composition |
EP3020411A1 (en) | 2005-12-22 | 2016-05-18 | GlaxoSmithKline Biologicals s.a. | Vaccine |
GB0607088D0 (en) | 2006-04-07 | 2006-05-17 | Glaxosmithkline Biolog Sa | Vaccine |
WO2009000825A2 (en) | 2007-06-26 | 2008-12-31 | Glaxosmithkline Biologicals S.A. | Vaccine comprising streptococcus pneumoniae capsular polysaccharide conjugates |
EA201001479A1 (en) | 2008-04-16 | 2011-06-30 | Глаксосмитклайн Байолоджикалс С.А. | VACCINE |
GB201003920D0 (en) | 2010-03-09 | 2010-04-21 | Glaxosmithkline Biolog Sa | Method of treatment |
GB201003924D0 (en) | 2010-03-09 | 2010-04-21 | Glaxosmithkline Biolog Sa | Immunogenic composition |
WO2012156391A1 (en) | 2011-05-17 | 2012-11-22 | Glaxosmithkline Biologicals S.A. | Vaccine against streptococcus pneumoniae |
GB201518684D0 (en) | 2015-10-21 | 2015-12-02 | Glaxosmithkline Biolog Sa | Vaccine |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5846547A (en) * | 1996-01-22 | 1998-12-08 | Regents Of The University Of Minnesota | Streptococcal C5a peptidase vaccine |
DE69737125T3 (en) * | 1996-10-31 | 2015-02-26 | Human Genome Sciences, Inc. | Streptococcus pneumoniae antigens and vaccines |
CN1253589A (en) * | 1997-04-24 | 2000-05-17 | 美国明尼苏达州大学 | Human complement C3-degrading proteinase from streptococcus pneumoniae |
CN1291233A (en) * | 1997-09-24 | 2001-04-11 | 美国明尼苏达州大学 | Human complement (3-degrading proteinase from i (streptococcus pheumoniae) |
-
1999
- 1999-09-24 EP EP99969446A patent/EP1115875A1/en not_active Withdrawn
- 1999-09-24 MX MXPA01003073A patent/MXPA01003073A/en unknown
- 1999-09-24 CN CN99813016A patent/CN1352691A/en active Pending
- 1999-09-24 BR BR9914066-7A patent/BR9914066A/en not_active Application Discontinuation
- 1999-09-24 CA CA002343931A patent/CA2343931A1/en not_active Abandoned
- 1999-09-24 JP JP2000574269A patent/JP2002526082A/en not_active Withdrawn
- 1999-09-24 KR KR1020017003811A patent/KR20010089280A/en not_active Application Discontinuation
- 1999-09-24 IL IL14201799A patent/IL142017A0/en unknown
- 1999-09-24 AU AU60608/99A patent/AU6060899A/en not_active Abandoned
- 1999-09-24 WO PCT/US1999/022362 patent/WO2000017370A1/en not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
CA2343931A1 (en) | 2000-03-30 |
JP2002526082A (en) | 2002-08-20 |
CN1352691A (en) | 2002-06-05 |
MXPA01003073A (en) | 2002-04-24 |
KR20010089280A (en) | 2001-09-29 |
IL142017A0 (en) | 2002-03-10 |
EP1115875A1 (en) | 2001-07-18 |
WO2000017370A1 (en) | 2000-03-30 |
BR9914066A (en) | 2002-04-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU6060899A (en) | Human complement c3-degrading polypeptide from (streptococcus pneumoniae) | |
AU9510598A (en) | Human complement c3-degrading proteinase from (streptococcus pneumoniae) | |
JP5122703B2 (en) | Streptococcus C5a peptidase vaccine | |
US5882897A (en) | yitJ | |
OA10742A (en) | Proteinase k resistant surface protein of neisseria meningitidis | |
JP2000512487A (en) | New compound | |
JP2001508650A (en) | Novel bacterial polypeptides and polynucleotides | |
JP2007500726A5 (en) | ||
JP2007500726A (en) | Immunogenic composition for Streptococcus pyogenes | |
JP2000509246A (en) | New compound | |
Hu et al. | Morganella morganii urease: purification, characterization, and isolation of gene sequences | |
EP0781340B1 (en) | Vaccine against group A Streptococcal infection | |
US5965402A (en) | DNA encoding phoH polypeptides | |
US6676943B1 (en) | Human complement C3-degrading protein from Streptococcus pneumoniae | |
AU740153B2 (en) | Human complement C3-degrading proteinase from streptococcus pneumoniae | |
CA2239836A1 (en) | Novel arginine deiminase | |
JP2001510990A (en) | Novel prokaryotic polynucleotides, polypeptides and uses thereof | |
AU2420800A (en) | Human complement C3-degrading polypeptide from streptococus pneumoniae | |
MXPA00002932A (en) | Human complement c3-degrading proteinase from streptococcus pneumoniae | |
WO2001025440A1 (en) | C3 binding polypeptide of streptococcus agalactiae, group b streptococcus | |
JPH11235183A (en) | Signal recognition particle polypeptide and polynucleotide | |
JPH11332580A (en) | New amps | |
JPH11505130A (en) | Novel cell surface protein compounds | |
JPH11225777A (en) | Novel gapdh | |
JPH11164696A (en) | New phosphoribosyl transferase |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MK1 | Application lapsed section 142(2)(a) - no request for examination in relevant period |